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Summary 
 
Prion diseases are infectious neurodegenerative conditions affecting humans and a 
wide variety of animals. The post-translational conversion of host-encoded cellular prion 
protein (PrPC) into an abnormal aggregation-prone isoform, designated PrPSc, is a 
central feature in the pathogenesis of prion diseases. 
The neuronal loss and spongiosis occurring in the central nervous system (CNS) of 
affected individuals may result from a toxic gain-of-function of aggregated PrPSc species. 
However, the contribution of a loss-of-function or dysfunction of PrPC in the 
pathogenesis of the disease cannot be excluded. Therefore, gaining insight into the yet 
unclear physiological function of PrPC is of crucial importance for the understanding of 
prion pathologies. 
Transgenic mice expressing amino-truncated versions of the prion protein (PrPΔN) suffer 
from spontaneous neurodegeneration. Coexpression of wild-type PrPC rescues the 
phenotype, suggesting the amino-terminus is crucial for the physiological function of 
PrPC. In the first part of my thesis, I examined whether the amino-terminus was not only 
necessary but also sufficient to convey the function of the full-length protein. To do so, I 
generated a transgenic mouse expressing a redacted version of PrPC consisting solely 
of its amino-terminus (PrPΔ141−231). However, because most of the structured domain of 
the full-length protein is deleted, the resulting protein is unstable and the expression 
level low. This limits the conclusions that can be drawn from the crossing experiments 
which show absence of rescue of the phenotype elicited by PrPΔΝ upon PrPΔ141−231 
coexpression. 
The mechanisms of transmission of prion diseases among animals are unknown. 
Hypotheses include oral and cutaneous portals of entry. The identification of novel 
infection routes is of interest since it may lead to reevaluate tissues and organs 
otherwise though to be prion free. In the second part of my thesis, I assessed the nasal 
cavity as a potential entry site for prions. Given the proximity of the nasal cavity with the 
central nervous system, I hypothesized that prion transmission upon nasal inoculation 
occurs in the absence of a replicative step in the lympho-reticular system. In a first set of 
experiments, I show that the nasal pathway is an entry site for prions. In a second, 
ongoing set of experiments, we examine the requirement of the lympho-reticular system 
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for prion transmission from the nasal cavity by using mouse models with various 
degrees of immunodeficiency.  
Zusammenfassung 
 
Prionenerkrankungen sind infektiöse neurodegenerative Krankheiten, die Menschen und 
zahlreiche verschiedene Tierarten befallen können. Dabei ist die post-translationale 
Konversion des zelleigenen Prion-Proteins (PrPC) zu einer aggregationsanfälligen 
Isoform, die PrPSc genannt wird, ein typisches Kennzeichen für Prionenerkrankungen. 
Die bei diesen Erkrankungen auftretenden Spongiosen im zentralen Nervensystem 
(ZNS) könnten von einem toxisch wirkenden gain-of-function Effekt des aggregierten 
PrPSc verursacht werden. Allerdings kann auch ein loss-of-function Effekt oder eine 
Fehlfunktion von PrPC als Ursache für die pathologischen Veränderungen bei diesen 
Erkrankungen nicht ausgeschlossen werden. Deswegen ist die Aufklärung der immer 
noch unklaren physiologischen Funktion von PrPC entscheidend für das Verständnis von 
Prionenerkrankungen. 
Transgene Mäuse, die eine amino-terminal verkürzte Version des Prionproteins (PrPΔN) 
exprimieren entwickeln eine spontane neurodegenerative Erkrankung. Dieser Phänotyp 
kann durch Co-expression von Wildtyp-PrPC rückgängig gemacht werden, was darauf 
hinweist, dass der Aminoterminus wichtig für die physiologische Funktion von PrPC ist. 
Im ersten Teil meiner Doktorarbeit untersuchte ich, ob der Aminoterminus nicht nur 
notwendig ist, sondern auch ausreicht um die Funktion des vollständigen Proteins zu 
erfüllen. Um das zu erreichen, stellte ich transgene Mäuse her, die eine modifizierte 
Version von PrPC, die nur aus dem Aminoterminus besteht (PrPΔ141−231), exprimieren. 
Da der grösste Teil der strukturierten Domäne des vollständigen Proteins fehlt, ist das 
resultierende Protein instabil und schwach exprimiert. Deswegen können aus den 
Kreuzungsexperimenten, die zeigen, dass die Co-expression von PrPΔ141−231 mit PrPΔN 
den PrP ΔN-Phänotyp nicht rückgängig macht, nur begrenzt Schlüsse gezogen werden. 
Die Mechanismen der Prionenübertragung zwischen Tieren sind unbekannt. Orale oder 
kutane Eintrittswege werden vermutet. Die Identifikation neuer Infektionswege ist von 
Bedeutung, da dies zur Re-evaluation von Geweben und Organen führen könnte, die 
bislang als prionenfrei galten. Im zweiten Teil meiner Doktorarbeit, untersuchte ich, ob 
die Nasenhöhle eine mögliche Eintrittstelle für Prionen sein könnte. Aufgrund der Nähe 
der Nasenhöhle zum ZNS, nahm ich an, dass Prionenübertragung nach nasaler 
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Inokulation ohne einen Replikationsschritt im lympho-retikuären System auskommt. 
Meine ersten Experimente zeigen, dass die Nasenhöhle eine Eintrittstelle für Prionen ist. 
In den darauffolgenden Experimenten, die noch nicht abgeschlossen sind, untersuchen 
wir anhand von Mausmodellen mit unterschiedlichen Graden von Immundefizienz, ob 
das lympho-retikuläre System notwendig für die Prionentransmission von der 
Nasenhöhle zum ZNS ist. 
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Abbreviations 
 
 
AA  amino acid 
 
bp  base pair 
 
cDNA  complementary DNA 
 
CJD  Creutzfeldt-Jakob disease 
 
fCJD  familial Creutzfeldt-Jakob disease 
 
sCJD  sporadic Creutzfeldt-Jakob disease 
 
vCJD  variant Creutzfeldt-Jakob disease 
 
CNS  central nervous system 
 
CWD  chronic wasting disease 
 
DNA  deoxyribonucleic acid 
 
dpi  days post inoculation 
 
Dpl  Doppel 
 
ELISA  enzyme-linked immunoassay 
 
FDC  follicular dendritic cell 
 
FFI  familial fatal insomnia 
 
GAPDH glyceralaldehyde 3-phospate deghydogenase 
 
GFAP  glial acidic fibrillary protein  
 
GPI  glycosylphosphatidylinositol 
 
GFAP  glial acidic fibrillary protein 
 
GSS  Gerstmann-Sträussler-Scheinker disease 
 
H-E  hematoxylin and eosin 
 
HRP  horseradish peroxidise 
 
i.c.   intracerebral 
 
i.p.  intraperitoneal 
 
kD  kilo Dalton 
 
LRS  lympho-reticular system 
 
LT  lymphotoxin 
 
ORF  open reading frame 
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PK  proteinase K 
 
PrPC  cellular prion protein 
 
PrPSc  abnormal, disease associated isoform of the prion protein 
 
PrP  refers to both PrPC and PrPSc  
 
PrPΔN in this work, designates amino-terminally truncated PrP variants with deletions extending 
into the hydrophobic core 
PrPR putative receptor of PrPC 
 
Prnd murine Dpl gene 
 
Prnp  murine PrPc gene 
 
PRNP human PrPc gene 
 
Prnp0/0 Prnp knock-out mouse  
 
RML Rocky mountain laboratory (mouse adapted sheep prion strain) 
 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
 
TME  transmissible mink encephalopathy 
 
TNF  tumor necrosis factor 
 
TSEs  transmissible spongiform encephalopathies 
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I. Introduction 
 
 
1. Prion diseases 
1.1 Definition of prion diseases 
Prion diseases are rare fatal neurodegenerative disorders affecting both humans and 
animals. They bear morphological and pathophysiological similarities with other 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, but are 
unique in that they are transmissible. In reference to their infectious nature and the 
typical spongiform degeneration that occurs in the central nervous system (CNS) of 
affected individuals (figure 1), prion diseases are also referred to as transmissible 
spongiform encephalopathies (TSEs). 
The nature of the infectious agent causing TSEs, called the prion, has not been 
determined with certainty.  The most widely accepted hypothesis suggests that PrPSc, a 
misfolded β-sheet rich version of the normal host prion protein PrPC is a critical, if not the 
only component of the prion (Prusiner 1982) (Weissmann 1991). 
 
 
Figure 1 
Neuropathological features of transmissible spongiform encephalopathies. Histological and 
immunohistochemical analysis of frontal cortex samples from the brain of a patient who died of non-
cerebral causes (upper row) and of a patient with Creutzfeldt-Jakob disease (CJD; lower row). Brain 
sections were stained with haematoxylin-eosin (H-E, left panels), with antibodies against glial fibrillary 
acidic protein (GFAP, middle panels) and with antibodies against the prion protein (PrP, right panels). 
Neuronal loss and prominent spongiosis are visible in the H-E stain. Strong proliferation of reactive 
 12 
astrocytes (gliosis) and perivacuolar prion protein deposits are detectable in the GFAP and PrP 
immunostains of the CJD brain samples. From Aguzzi et al., Nat Rev Neurosci, 2001. 
 
 
1.2 A historical perspective 
 
The first record of prion diseases dates back to mid-18th-century England, when a 
spreading disease in sheep, then one of the most widely exchanged goods,  alarms the 
British parliament (Brown and Bradley 1998).  Affected animals typically develop tremor, 
ataxia and pruritus, leading them to scrape or bite the affected areas. The name of the 
disease, scrapie, derives from this behaviour (Lampert, Gajdusek et al. 1972). The 
transmissible nature of the disease is recognized very early, but is first proven in 1936 
by Cuillé and Chelle who successfully transmit scrapie to two healthy sheep by 
intraocular inoculation of CNS tissue derived from an affected animal  (Cuillé 1936). Ten 
years later, the infectious property of the scrapie agent is involuntarily confirmed in 
England following an outbreak of scrapie among sheep immunized against louping-ill 
with a vaccine manufactured with CNS and spleen tissue of scrapie-affected animals 
(Gordon 1946). However, the aetiology of the disease remains a mystery, and 
speculations include a parasitic or viral origin (Plummer 1946).  
In the 1950’s, the Fore people, inhabitants of Papua-New Guinea, come to the attention 
of the scientific community. Australian anthropologists Ronald and Catherine Berndt 
report a unique neurological condition, locally called kuru, restricted to the Fore people 
and reaching epidemic proportions (Berndt 1954). The aetiology of kuru is obscure, but 
seems to be linked to ritualistic endocannibalism (Goldfarb 2002). The interest of 
American paediatrician and virologist Gajdusek is tickled (Gajdusek and Zigas 1957), 
and he conducts a series of inoculation experiments leading to the proof of 
transmissibility of kuru to chimpanzees (Gajdusek, Gibbs et al. 1966). In 1959, 
neuropathologist Klatzo points out the similarity between kuru and another human 
neurological condition of unknown aetiology, described in the early 1920’s by two 
German neurologists Creutzfeldt and Jacob (Creutzfeldt 1920) (Jakob 1921) (Klatzo, 
Gajdusek et al. 1959). Similarly to kuru, Creutzfeldt-Jakob disease (CJD)  is shown to be 
transmissible to chimpanzees (Gibbs, Gajdusek et al. 1968). The same year, the 
American veterinary neuropathologist Hadlow suggest an analogy between kuru and  
the sheep disease scrapie, based on the striking similarities of the neuropathologic 
findings (Hadlow 1995). Scrapie, kuru and CJD are believed to share the same aetiology 
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(Lampert, Gajdusek et al. 1972), but the nature of the infectious agent is debated. Until 
the 1980’s, the scientific community favours a slow viral origin, which explains both the 
infectious nature and the unusually long incubation period of the diseases (Lampert, 
Gajdusek et al. 1972) (Gajdusek 1977).  
The first step towards discovering what is now widely accepted as the causative agent 
of prion diseases is made by British radiopathologist Alper. In 1966, on the basis of 
experiments showing the absence of inactivation of the scrapie infectious agent 
following exposure to ultra-violet (UV) light (Alper, Haig et al. 1966), she suggests that 
the scrapie agent has the unique property of being able to replicate in the absence of 
nucleic acids (Alper, Cramp et al. 1967) (Alper, Haig et al. 1978). A year later, this 
revolutionary idea is supported by a mathematical model proposed by Griffith, who 
suggests that under certain circumstances, proteins are able to self-replicate (Griffith 
1967).  
Fifteen years later,  American neurologist and biochemist Prusiner demonstrates that 
the scrapie agent is resistant to procedures inactivating nucleic acids, but is sensitive to 
treatments denaturing or hydrolysing proteins (Prusiner 1982). Based on these findings, 
he proposes that the scrapie agent, and by extension the causative agent of all other 
prion diseases, is a proteinaceous molecule devoid of nucleic acids. This ‘protein-only 
hypothesis’ further suggests that an abnormal isoform of the host-encoded cellular prion 
protein (PrPC) is the principal and possibly the only constituent of the transmissible 
agent (Bolton, McKinley et al. 1982) (Prusiner 1982). This abnormal isoform, called 
PrPSc, induces a conformational change in PrPC, turning it into a like of itself (Weissmann 
1991).  
The demonstration that Prnp knock-out mice are resistant to prion infection (Bueler, 
Aguzzi et al. 1993) and that prion diseases can be caused by a mutation in the host 
prion protein gene support the protein only hypothesis which is now widely accepted 
among the scientific community. 
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1.3 Animal prion diseases 
 
Naturally occurring animal prion diseases include sheep scrapie, the prototypical animal 
prion disease, bovine spongiform encephalopathy (BSE), chronic wasting disease 
(CWD) in deer and elk and transmissible mink encephalopathy (TME).  
Scrapie is an enzootic disease of sheep first reported in the 18th century, more prevalent 
in the northern than in the southern hemisphere. Epidemiological studies on 
transmissibility of scrapie to humans have never shown a causal effect (Chatelain, 
Cathala et al. 1981), and scrapie is not considered a zoonosis (Smith and Bradley 2003). 
Unlike scrapie, the discovery of the other naturally occurring animal TSEs is more recent.  
The first case of BSE, also called “mad cow disease” is thought to have occurred in 
1985 in the United Kingdom (Bradley 2001), although a French report from the late 19th 
century describes a case clinically similar to BSE in an ox (Sarradet 1883). The origin of 
this first case is unknown, and speculations include transmission of scrapie to cattle or a 
rare sporadic occurrence of the disease in cattle (Smith and Bradley 2003). The 
epidemic spread of the disease in the UK during the late 1980’s to mid 1990’s is 
attributed to transmission of cattle-adapted scrapie or BSE to cattle via contaminated 
feed prepared from rendered carcasses, called meat and bone meal (MBM) (Horn 2001). 
The epidemic, which peaked in 1993, was controlled by banning ruminant offal as raw 
material for the preparation of dietary supplements destined for feeding to cattle or other 
ruminants (Sellier 2003).  BSE was subsequently detected in other European countries, 
although to a lower extent than in the UK. It is hypothesized that these cases result from 
exportation of cattle, cattle products or meat and bone meal (MBM) from the UK (Smith 
and Bradley 2003). The higher incidence observed in the UK is suggested to be due to 
several circumstances, including a high ratio of sheep to cattle, a high enzootic 
prevalence of scrapie in sheep, the intensive feeding of MBM to dairy cattle and the 
changes in rendering practices (Prusiner 2004). 
CWD is a TSE of captive and free-ranging mule deer, white-tailed deer and Rocky-
Mountain elk (Williams and Young 1992). The first cases of CWD are recognized among 
captive mule deer in the late 1960’s in Colorado. However the prion aetiology of the 
disease is first  appreciated in 1977 (Williams and Young 1980).  In contrast to scrapie 
and BSE, where the clinical manifestations of the disease are predominantly 
neurological, loss of body condition and emaciation are the prominent features of CWD 
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(Sigurdson 2008). Since the 1960’s, CWD has widely spread in North America following 
natural movement of animals along migration corridors.  
TME is a rare sporadic disease of ranched mink, first recognized in 1947 in Wisconsin 
and Minnesota (Marsh and Hadlow 1992). Outbreaks in the 1960’s are epidemiologically 
associated with consumption of feed of ovine or bovine origin (Hartsough and Burger 
1965), and an unrecognized case of BSE has been suggested as the cause of TME 
(Marsh, Bessen et al. 1991).  
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1.4 Human prion diseases 
 
Human prion diseases are unique in that the disease process can be triggered through 
an inherited germline mutation in the prion protein gene (PRNP), through infection 
following exposure to PrPSc or sporadically through the rare spontaneous conversion of 
PrPC into PrPSc. 
Sporadic CJD (sCJD) is the most frequent type of human prion diseases, accounting for 
85% of all cases. It is  rare, with an incidence of 1-2 cases per million population per 
year across the world (Brown, Cathala et al. 1987). sCJD has no obvious infectious or 
genetic aetiology, and is postulated to be caused by a somatic mutation in the human 
prion gene PRNP or alternatively by the rare spontaneous conversion of PrPC into PrPSc 
(Collinge 1997). The transmissibility of  sCJD to non human primates was first 
demonstrated in 1968  (Gibbs, Gajdusek et al. 1968). Clinically, sCJD is a rapidly 
progressive multifocal dementia, usually accompanied by myoclonus. The peak of onset 
is between 60-65 year, and death occurs within 2-3 months (Wadsworth, Hill et al. 2003). 
Neuropathological findings include the classical triad of neuronal loss, astrogliosis and 
spongiform change (figure 1). PrP amyloid plaques are usually not present (Budka, 
Aguzzi et al. 1995). 
About 15% of human prion diseases are familial (inherited), associated with a mutation 
in PRNP. To date, more than 50 mutations have been identified and  linked to a familial 
prion diseases (Prusiner 2004). Familial prion diseases are further sub-classified 
according to the clinical manifestations of the disease, although a high degree of 
phenotypic overlap exists between individuals with different mutations (Collinge, Brown 
et al. 1992). The most frequent familial prion disease is familial CJD (fCJD), and over 20 
mutations co segregate with this disease. Clinically, fCJD is very heterogeneous but 
classically resembles sCJD (Parchi, Castellani et al. 1996). Fatal Familial insomnia (FFI) 
is most frequently associated with a D178N missense mutation. Progressive untreatable 
insomnia, dysautonomia, dementia and selective thalamic degeneration classically 
characterize this disease (Medori, Tritschler et al. 1992). Gerstmann-Sträussler-
Scheinker disease (GSS) is most commonly associated with a P101L substitution. 
Chronic cerebellar ataxia with pyramidal features are the initial signs of the diseases, 
dementia occurring much later in the clinical course. The duration of the disease is 
typically longer than in sCJD  (Gerstmann 1928) (Collinge 1997). The mechanisms by 
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which these mutations trigger the disease remain to be uncovered, but it is speculated 
that the prion protein bearing a pathogenic mutation has a high propensity to convert 
spontaneously to the infectious isoform (Prusiner 1989). Experimental transmission of  
fCJD (Roos, Gajdusek et al. 1973) and GSS (masters 1981) to non-human primates and 
FFI to mice (Tateishi, Brown et al. 1995) proved the infectious nature of these genetic 
diseases. 
Acquired prion diseases are the rarest form of human TSEs. They include prion 
diseases transmitted by iatrogenic contact with infected human material (such as dura 
mater or growth hormone derived from human cadavers) or by dietary exposure to 
prions, such as kuru or variant CJD (vCJD). vCJD was first described in 1996 in the UK 
(Will, Ironside et al. 1996). Clinically, the initially predominantly psychiatric disturbances, 
the early onset of disease and the comparatively long clinical course clearly distinguish 
vCJD from other human prion disease. Neuropathologically, vCJD cases display large 
numbers of PrP-containing amyloid plaques, a feature that is rarely found in sCJD 
(Budka, Aguzzi et al. 1995). Based on epidemiological, neuropathological and 
biochemical findings, vCJD is believed to arise from ingestion of BSE contaminated beef 
(Collinge and Rossor 1996) (Weissmann and Aguzzi 1997).  
In addition to the mutations linked to inheritable prion disease, 16 polymorphisms have 
been identified in PRNP. A coding polymorphism at codon 129 of PRNP is a strong 
susceptibility factor for human prion diseases. About 38% of Europeans are 
homozygous for the more frequent methionine allele, 51% are heterozygous, and 11% 
homozygous for valine (Wadsworth et al. 2007). Homozygocity for methionine at codon 
129 (M/M) predisposes to sporadic and acquired CJD (Collinge, Palmer et al. 1991) 
(Palmer, Dryden et al. 1991). The polymorphism also affects the disease course of 
iatrogenic CJD, with  heterozygotes (methionine/valine) displaying a longer incubation 
time (Huillard d'Aignaux, Costagliola et al. 1999).  
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1.5 Yeast and filamentous fungi prions 
 
Prions can be broadly defined as infectious proteins that do not require a nucleic acid for 
infectivity. Such proteins have been identified in yeast and filamentous fungi, and are 
commonly referred to as yeast prions. Their amino acid sequence does not bear any 
homology with PrPC, but like mammalian prions, yeast prions consist of altered versions 
of normal cellular proteins which impose their conformation onto their normal 
counterpart to propagate. Up to now six yeast prions have been identified, four of which 
are amyloidogenic and two others consisting of self-activating enzymes (Wickner, 
Edskes et al. 2007). The amyloidogenic yeast prions bare similarities with PrPSc in that 
they aggregate and form amyloid fibrils. But in contrast to mammalian prions, they are 
not pathogenic, and protein aggregation is associated with loss of function of the normal 
protein.   
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2. The cellular prion protein and its abnormal isoform 
 
2.1. Biosynthesis, trafficking and cleavage of the cellular prion protein 
 
The mouse PrPC polypeptide consists of 254 amino-acids. A 22 amino-acid signal 
sequence targets PrPC to the endoplasmatic reticulum (ER) and after translocation, 23 
hydrophobic amino-acids  are cleaved off from the carboxy-terminus and replaced by a 
glycosyl phosphatidyl inositol (GPI) anchor (Stahl, Borchelt et al. 1987), giving rise to a 
209 amino acid protein. In the ER and Golgi, the 25 kD protein is facultatively 
glycosylated at two asparagine residues, giving rise to un-, mono- and diglycosylated 
PrPC species (Bolton, Meyer et al. 1985)  (Haraguchi, Fisher et al. 1989). The mature 
protein is transported via secretory granules to the cell membrane, to which it is 
attached by its GPI anchor.  PrPC is located in cholesterol and sphingolipid rich 
microdomains of the membrane, called lipid rafts (Vey, Pilkuhn et al. 1996) (Naslavsky, 
Stein et al. 1997).  
The protein constitutively cycles between the plasma membrane and early endosomes. 
The mechanism of PrPC internalization is still controversial and both clathrin-dependant 
endocytosis (Shyng, Heuser et al. 1994) (Taylor, Watt et al. 2005) and a caveola-
mediated endocytosis (Vey, Pilkuhn et al. 1996) (Kaneko, Vey et al. 1997) (Marella, 
Lehmann et al. 2002) (Peters, Mironov et al. 2003) have been reported.  
Two posttranslational cleavages occur as part of the normal metabolism of PrPC (Mange, 
Beranger et al. 2004) (Hooper 2005). One cleavage takes place within the GPI and 
releases the polypeptide chain into the extracellular matrix (ECM) (Borchelt, Scott et al. 
1990). The second cleavage is proteolytic (α cleavage) and occurs within a segment of 
16 hydrophobic amino acids that is conserved in all cloned PrPC species (Harris, Huber 
et al. 1993). This cleavage gives rise to a soluble amino-terminal fragment (N1) and a 
GPI-anchored carboxy-terminal fragment (C1) that can no longer be converted into 
PrPSc (Harris, Huber et al. 1993) (Jimenez-Huete, Lievens et al. 1998) (figure 2).  
Upon exposure to reactive oxygen species (ROS), PrPC was shown to be cleaved in 
vitro within or adjacent to the octarepeat region (β-cleavage), to generate N2 and C2 
fragments (McMahon, Mange et al. 2001) (figure 2). The C2 fragment was also detected 
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specifically in the brain of patients suffering from CJD (Chen, Teplow et al. 1995). The 
significance of both the α and β cleavages of PrPC remains to be determined. 
 
 
 
 
 
Figure 2 
α- and β-cleavage of mouse PrPC. A Schematic representation of mouse PrPC. Amino- and carboxy-
terminal signal peptides, octarepeat region, N-linked glycosylation sites, disulfide bridge and attachment 
of the GPI anchor are represented. The α-cleavage site is located at position 111/112; the β-cleavage site 
is located in the octarepeat region, near histidine position 96. B Nomenclature of the PrPC fragments 
generated by the α- and β-cleavage.  Adapted from Mangé et al., Biol Cell, 2004. 
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2.2 Expression pattern of the cellular prion protein 
  
The cellular prion protein is highly conserved among mammals (Rivera-Milla, Stuermer 
et al. 2003) (Westaway and Carlson 2002) (figure 3) and orthologs have been identified 
in other vertebrates such as marsupial (Windl, Dempster et al. 1995), chicken (Harris, 
Lele et al. 1993) and fish (Rivera-Milla, Stuermer et al. 2003). Murine, hamster and 
human PrP genes were cloned in 1986  (Locht, Chesebro et al. 1986) (Basler, Oesch et 
al. 1986) (Liao, Lebo et al. 1986). In all known mammalian PrPC genes, a single open 
reading frame encodes the protein. Within the genome, the PrPC gene is present in a 
single copy. The mRNA is constitutively expressed in the adult organism and 
developmentally regulated during mouse embryogenesis (Manson, West et al. 1992) 
(Miele, Alejo Blanco et al. 2003). PrPC is ubiquitously expressed although most 
abundantly in the CNS (Ford, Burton et al. 2002) (Bendheim, Brown et al. 1992). Within 
the CNS, PrPC is most highly expressed by neurons, although astrocytes and 
oligodendrocytes also express it (Moser, Colello et al. 1995) (Sales, Hassig et al. 2002). 
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Figure 3 
Alignment of deduced amino acid sequences of human, gorilla, chimp, bovine, sheep, mink, rat, 
mouse and hamster prion proteins. Dots represent amino acids that are identical with the human PrPC 
sequence. Lines represent amino-acids that do not exist in the respective sequence. The most conserved 
region of the prion protein is a hydrophobic stretch that spans from amino acid 112 to 136 (human 
numbering), called the hydrophobic core (HC, in light green). Adapted from Van Rheede et al., Mol Biol 
Evol, 2003. 
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2.3 Structure of the cellular prion protein 
 
PrPC consists of a highly structured carboxy-terminus and a flexible amino-proximal 
domain. The globular carboxy-terminal domain (mouse amino acid residues 135-231) 
comprises three α-helices (mouse amino acid residues 141-154, 175-193 and 200-219) 
and an anti-parallel β-sheet (mouse amino-acid residues 128-131 and 161-164). A 
disulphide bridge connects helix 2 and 3, and residue 180 and 196 are two facultative N-
glycosylation sites (Riek, Hornemann et al. 1996) (Riek, Hornemann et al. 1997).  
Knock-in mice carrying point mutations disrupting one or both N-glycosylation sites 
(N180T, N196T, N180T/N196T) are normal, although complete blockade of 
glycosylation (N180T/N196T) leads to a predominantly intracellular location of PrPC 
(Cancellotti, Wiseman et al. 2005). Transgenic mice overexpressing a deglycosylated 
isoform of PrPC are susceptible to scrapie and BSE (Neuendorf, Weber et al. 2004), 
indicating that glycosylation is dispensable for prion replication. 
Four defined regions are recognized within the flexible amino-terminal domain of PrPC 
(amino acid residues 23-134). First, a stretch of five positively charged amino acids 
situated at the very amino-terminus and called charged cluster 1 (CC1, mouse amino 
acids 23-27), that has been shown to be crucial for PrPC internalisation (Sunyach, Jen et 
al. 2003) (Taylor, Watt et al. 2005). Second, a copper binding region consisting of a 
segment of four (murine PrPC) or five (human PrPC) repeats of a sequence of eight 
amino acids, called the octarepeat region (OR, mouse amino acids 60-91). Transgenic 
mice expressing PrPC variants lacking the OR develop normally (Fischer, Rulicke et al. 
1996) (Shmerling, Hegyi et al. 1998) (Muramoto, DeArmond et al. 1997) and propagate 
prions efficiently, indicating that the OR is neither of crucial importance for the 
physiological function of PrPC nor for the conversion to PrPSc. But interestingly, 
transgenic mice expressing a PrPC variant with nine supernumerary octapeptide repeats, 
modelling a fCJD mutation, develop a cerebellar disorder (Chiesa, Drisaldi et al. 2000). 
The disease is not transmissible, and cannot be rescued by co-expression of the full-
length protein (Chiesa, Piccardo et al. 2003). The third domain, called charged cluster 2 
(CC2, amino acids 95-110) precedes a highly conserved region, the hydrophobic core 
(HC, amino acids 111-134) (figure 3). While transgenic mice expressing PrPC variants 
with disrupted CC2 regions do not develop a phenotype, disruption of the HC leads to 
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spontaneous neurodegeneration (Baumann, Tolnay et al. 2007) (Li, Christensen et al. 
2007), suggesting an important role for the HC in the physiological function of PrPC. 
 
 
 
 
 
Figure 4 
Structural features of the cellular prion protein. A Primary structure of the cellular prion protein 
including post-translational modifications. The numbers describe the position of the respective amino 
acids. SS (yellow) indicates the signal sequence; CC1 (pink) represents the charged cluster 1; OR 
(purple) designates the octarepeat region; CC2 (dark blue) represents the charged cluster 2 and HC 
(orange) the hydrophobic core. The beta sheets are depicted in green and the alpha helices in red. S-S 
indicates the disulphide bridge. GPI denotes the membrane anchorage region. B Tertiary structure of the 
cellular prion protein inserted into a lipid bilayer, as deduced from NMR spectroscopy, including the 
unstructured amino-terminal region depicted in grey and the GPI anchor. Adapted from Aguzzi et al., Nat 
Rev Microbiol, 2006. 
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2.4 Physiological function of the cellular prion protein 
 
The role of PrPC in the pathogenesis of prion diseases is well established (Bueler, 
Aguzzi et al. 1993), but its physiological function remains unclear. One major draw-back 
towards understanding the physiological function of PrPC is the lack of phenotype in the 
CNS of Prnp0/0 mice (Bueler, Fischer et al. 1992). Furthermore, mice in which PrPC is 
post-natally deleted fail to develop a phenotype, arguing against the existence of other 
proteins that compensate for essential PrPC functions during development (Mallucci, 
Ratte et al. 2002). These findings suggest either redundancy of PrPC or the absence of a 
major function of the protein in the CNS. PrPC being a highly conserved protein most 
abundantly expressed in the CNS, the latter hypothesis is unlikely. 
Many functions are attributed to PrPC, supported by both in vitro and in vivo evidence, 
however a unified view of the function is still missing 
 
PrPC and apoptosis 
 
PrPC has been suggested to convey both pro- and anti-apoptotic signals.  
In cultured human foetal neurons, PrPC was found to  protect against Bax mediated 
apoptosis (Bounhar, Zhang et al. 2001)  (Roucou, Guo et al. 2003) (Roucou, 
Giannopoulos et al. 2005), and PrPC expression was shown to rescue Hpl cells from 
serum deprivation induced apoptosis (Kuwahara, Takeuchi et al. 1999).  
In contrast to these findings, overexpression of PrPC was shown to sensitize cultured 
cells to staurosporin induced death and increase caspase 3 activity (Paitel, Alves da 
Costa et al. 2002), and cross-linking of PrPC on the neuronal surface was shown to 
induce  apoptosis in hippocampal and cerebellar neurons in vivo (Solforosi, Criado et al. 
2004). 
 
PrPC and oxidative stress 
 
Oxidative stress plays a central role in the pathogenesis of neurodegenerative diseases 
(Halliwell 2006) and  PrPC has been suggested to be involved in cellular protection 
against oxidative stress. 
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Cerebellar granular and neocortical neurons isolated from Prnp0/0 mice were shown to 
be more susceptible than Prnp+/+ neurons to treatments with oxidative stress inducing 
agents (Brown, Schmidt et al. 1997) (Brown, Schulz-Schaeffer et al. 1997) (Buddi, Lin et 
al. 2002). Also, increased levels of oxidative stress markers were found in brains of 
Prnp0/0 mice compared to Prnp+/+ mice. In addition, brain lesions induced by hypoxia and 
ischemia are larger in Prnp0/0 mice than in wild-type mice (McLennan, Brennan et al. 
2004). The mechanisms underlying the putative protective effect of PrPC are 
controversial. It has been suggested that PrPC has a super oxide dismutase (SOD) 
activity (Brown, Wong et al. 1999),  but theses findings could not be confirmed  in vivo 
(Hutter, Heppner et al. 2003). 
 
PrPC and copper 
 
PrPC  binds copper via the octarepeats of its amino-terminus (Brown, Qin et al. 1997). 
Copper was shown to stimulate the endocytosis of PrPC (Pauly and Harris 1998) (Perera 
and Hooper 2001), suggesting that PrPC functions as a receptor for cellular uptake or 
efflux of copper ions. However, a correlation between  PrPC expression and the cellular 
or tissue content of copper could not be found in vivo (Waggoner, Drisaldi et al. 2000).  
 
PrPC as a signalling molecule 
 
Lipid rafts are specialized microdomains of the plasma membrane enriched in 
cholesterol and sphingolipids. Rafts are thought to play a facilitating role in signal 
transduction (Tsui-Pierchala, Encinas et al. 2002) . The presence of PrPC in lipid rafts 
suggests it participates in transmembrane signalling processes. Antibody cross-linking 
of PrPC on neuroectodermal cell line 1C11 was found to stimulate the activity of non-
receptor tyrosine kinase Fyn via interaction of PrPC with raft protein caveolin (Mouillet-
Richard, Ermonval et al. 2000), leading to downstream stimulation of NADPH oxidase 
and extracellular regulated kinases (Erks) as well as production of reactive oxygen 
species (ROS) (Schneider, Mutel et al. 2003). Also, PrPC was shown to facilitate neurite 
outgrowth via cis and trans interactions with NCAM to lipid rafts and activation of Fyn 
kinase (Santuccione, Sytnyk et al. 2005). However, in vivo confirmation of these findings 
is still missing. 
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2.5 Interaction partners 
 
A common strategy to elucidate the physiological function of a protein is to identify 
interacting partners. In the case of PrPC many different interacting partners have been 
described (Watts and Westaway 2007) (Aguzzi, Baumann et al. 2008). However, the 
lack of overlap between the putative interacting partners identified in different 
laboratories and the inability to prove functional relevance of the interactions in vivo 
have undermined the physiological relevance of these findings. 
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2.6 The disease associated-isoform of the prion protein 
 
This structural transition of PrPC to PrPSc is accompanied by profound changes in the 
physicochemical properties of the prion protein. While PrPC is soluble in mild detergents 
and sensitive to proteinase K (PK), PrPSc is insoluble, forms aggregates and is partially 
resistant to PK (Oesch, Westaway et al. 1985) (Meyer, McKinley et al. 1986). PK 
cleavage of PrPSc around amino acid residue 90  (McKinley, Meyer et al. 1991) gives 
rise to a fully infectious prion protein species, named PrP27-30 after its migration pattern 
on a SDS-PAGE (McKinley, Meyer et al. 1991) (figure 5). The insolubility of PrPSc 
prevents NMR studies, and first indications of differences in the secondary structure of 
the two PrP isoforms came from infra-red spectroscopic measurements. While PrPC is 
dominated by α-helices and has only little β-sheet content, PrPSc is characterized by 
similar amounts of α-helices and β-sheets (Caughey, Dong et al. 1991) (Safar, Roller et 
al. 1993).  
In most cases of naturally occurring and experimentally induced prion diseases, a 
correlation exists between PK resistance and infectivity, and PK resistant material is 
used as a surrogate marker for infectivity. However, it appears that disease associated 
isoforms of the prion protein can be PK sensitive (Lasmezas, Deslys et al. 1997) (Hsiao 
telling1994), and that PK resistant PrP is not always infectious (Chiesa 2000). 
 
 
 
Figure 5 
Schematic drawing of PrPC and PrPSc before and after Proteinase K (PK) digestion. The mature 
human prion protein contains 209 amino acids. The five light grey boxes indicate the octarepeats of the 
amino-terminal domain. PrPC and PrPSc have an identical amino acid sequence and share the same 
posttranslational modifications, but differ in their secondary and (presumably) tertiary structure. The 
physiological isoform PrPC is protease-sensitive, while the pathological isoform PrPSc is partially protease 
resistant, displaying a protease-resistant core designated PrP27-30. Adapted from Aguzzi et al., Cell Death 
Differ, 2000. 
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3. Mechanisms of prion transmission and neurodegeneration 
 
3.1. Conversion of PrPC into PrPSc 
 
Mechanisms of conversion 
 
According to the protein-only hypothesis, the disease associated isoform of the prion 
protein propagates by imposing its conformation onto the normal cellular protein PrPC, 
turning it into a like of itself (Prusiner 1982).  PrPSc then accumulates in the brain of 
affected individuals, either as amorphous deposits or as highly structured amyloid 
(Budka, Aguzzi et al. 1995). Two hypotheses have been formulated to explain the 
mechanisms leading to the conversion of PrPC into PrPSc (Weissmann 1999). The 
“refolding model” (figure 6a) suggests that PrPC can spontaneously refold into PrPSc, but 
that this phenomenon is prevented by a high activation energy barrier. In the presence 
of exogenous PrPSc, the reaction is facilitated. The “seeding (or nucleation) model” 
(figure 6b) proposes that PrPC and PrPSc are in equilibrium. PrPSc is stabilized when 
added onto an aggregate of PrPSc or seed. The initial formation of the seed is a rare 
event, but once formed, additional PrPSc molecules can add up onto the seed which 
grows and eventually breaks, leading to an exponential conversion rate. 
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Figure 6 
Models for the conformational conversion of PrPC to PrPSc. A The "refolding" model postulates an 
interaction between exogenously introduced disease-associated prion protein (PrPSc) and endogenous 
cellular prion protein (PrPC), which is induced to transform itself into more PrPSc. A high-energy barrier 
might prevent spontaneous conversion of PrPC into PrPSc. B The "seeding" model proposes that PrPC and 
PrPSc are in a reversible thermodynamic equilibrium. So, only if several monomeric PrPSc molecules are 
mounted in a highly ordered seed can more monomeric PrPSc be recruited and eventually aggregate to 
form an amyloid. In such crystal-like seed, PrPSc becomes stabilized. Fragmentation of PrPSc aggregates 
increases the number of nuclei, which can recruit more PrPSc, and so seems to result in replication of the 
agent. From Aguzzi et.al., Nat Rev Immunol, 2004. 
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Site of conversion 
 
The site of PrPSc generation is debated. PrPC, the substrate for PrPSc, is a GPI-anchored 
protein located in lipid rafts that constitutively recycles between the cell surface and an 
endocytic compartment. Upon each recycling event, a fraction of PrPC leaves the 
endocytic vesicles and is directed towards lysosomes for proteolysis. As part of its post-
translational processing, PrPC is cleaved within the GPI anchor, and the polypeptide 
chain is released into the extracellular matrix (Borchelt, Scott et al. 1990). Additionally, 
PrPC has been detected in the nucleus and the cytoplasm. 
The conversion of PrPC into PrPSc could thus include any of these compartments. 
Evidence supports conversion taking place in lipid rafts, as PrPC molecules bearing 
modifications in their cytoplasmatic tails leading to their redirection to clathrin pits were 
not converted (Taraboulos, Scott et al. 1995) (Kaneko, Vey et al. 1997). Other studies 
indicate that lipid rafts rather protect PrPC against conversion to PrPSc. Raft depletion by 
inhibition of sphingomyelin production increased scrapie infection in cultured cells 
(Naslavsky, Shmeeda et al. 1999), and cholesterol depletion increased the proportion of 
misfolded PrPC in the ER (Campana, Sarnataro et al. 2006) (Sarnataro, Campana et al. 
2004). More experimental data is hence needed to clarify these contradictory findings. 
Interestingly, PrPSc has been shown to accumulate in late exosomes, and increased 
exosome release increased the shedding of prions (Fevrier, Vilette et al. 2004) (Porto-
Carreiro, Fevrier et al. 2005). However, the site of PrPSc accumulation may not reflect 
the compartment in which the conversion takes place.  
 32 
3.2 Prion strains and species barrier 
 
Like conventional micro-organisms, prion agents exhibit strain variation. A prion strain is 
defined by the reproducible incubation time, histopathological features and lesion 
distribution it induces in identical hosts. These characteristics are  typically  stable upon 
serial transmission in inbred mice (Aguzzi, Heikenwalder et al. 2007). Prion strains have 
also been shown to differ in their clinical manifestations (Wadsworth, Hill et al. 2003), 
their tropism (Aguzzi, Sigurdson et al. 2007), and their ease of transmission to other 
species (Caughey 2003). The molecular basis underlying prion strains is not known, but 
in line with the protein-only hypothesis, strain-specific information has been proposed to 
be encoded within the tertiary or quaternary structure of PrPSc molecules (Peretz, Scott 
et al. 2001) (Collinge and Clarke 2007). Supporting this idea is the finding that PK 
digestion of PrPSc from two different mink prion strains (drowsy and hyper) produces 
different PrPSc fragment sizes, suggesting that the two strains have different 
conformations resulting in the exposure of different PK cleavage sites  (Bessen and 
Marsh 1994) (Bessen and Marsh 1992). Further structural analysis of prion strains using 
Fourier Transformed Infrared Spectroscopy (Aucouturier, Kascsak et al. 1999), 
conformation dependant immunoassays (Bellon, Seyfert-Brandt et al. 2003) and atomic 
force microscopy of synthetic prion polymers (Jones and Surewicz 2005) confirmed 
structural differences between prion strains. More recently, the use of a new series of 
conformation-specific protein dyes, called luminescent conjugated polymers (LCPs) 
(Nilsson, Herland et al. 2005), allowed to distinguish different prion strains based on the 
emission spectra of the dyes, further confirming the conformational differences between 
prion strains (Sigurdson, Nilsson et al. 2007).  
Serial transmission of the infectious agent to inbred animals is required to formally 
define a prion strain. However, surrogate biochemical properties such as the fragment 
sizes of PrPSc after PK digestion (Collinge, Sidle et al. 1996) (Parchi, Castellani et al. 
1996) and the prevalence of the three glycopatterns of PrP (Collinge, Sidle et al. 1996) 
are used when transmission experiments are not possible. Based on these biochemical 
properties, four types of sCJD, each associated with different clinicopathological 
phenotypes, have been defined  (Collinge, Sidle et al. 1996) (Collinge, Sidle et al. 1996). 
How these conformational differences in PrPSc molecules relate to strain-specific 
disease phenotypes remains to be clarified. 
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Transmission of prion diseases between different species is typically far less efficient 
than within species. The incubation time is often longer and the attack rate reduced. 
This phenomena is called the species barrier (Collinge and Clarke 2007), and it was 
initially proposed to be due to PrPC primary structure differences between donor and 
host. Supporting this suggestion is the finding that unlike wild-type mice, transgenic mice 
expressing hamster PrPC are highly susceptible to hamster prions (Scott, Foster et al. 
1989). However, transmission of sCJD prions to wild-type mice is very inefficient, while 
transmission of vCJD occurs much more readily (Hill, Desbruslais et al. 1997), although 
both strains share the same PrPC primary structure. This suggests that to yet unknown 
features in addition to the difference in PrPC primary structure affect the transmissibility 
of a prion strain to other species.  It is suggested that PrPC of each species is capable of 
a different range of PrPSc conformations, and that a given prion conformational variant 
can infect only those species for which the PrPC can assume that same conformation 
(Collinge and Clarke 2007). However, in order to verify this hypothesis, the determinants 
governing the possible prion conformational variants that a particular PrPC can assume 
must be elucidated. 
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  3.3 A central nervous system disease with peripheral involvement 
 
Lympho-reticular involvement in peripherally acquired prion diseases 
 
Many TSEs result from peripheral exposure to prions that eventually spread to the brain 
where their toxicity is revealed. BSE, vCJD and kuru are all attributed to dietary 
exposure to prions. The routes of horizontal prion transmission of scrapie, CWD and 
TME are unknown, but transdermal and oral portals-of-entry have been postulated.  
Studies in rodents have shown that after peripheral infection, an initial phase of prion 
replication takes place in secondary lymphoid organs, particularly the spleen and lymph 
nodes. Infectivity titres in the lymphoreticular tissues (LRT) reach a maximum well 
before infectivity is detectable in the brain, maintaining a plateau for the remainder of the 
disease progression (Aguzzi 2003) (Daude 2004). In the lymphoid tissue, Follicular 
dendritic cells (FDCs) are the main prion replication compartment (Klein, Frigg et al. 
1997) (Prinz, Montrasio et al. 2002), but PrPC-expressing haematopoietic cells are 
required for most efficient lymphoreticular prion propagation (Kaeser, Klein et al. 2001). 
B cells provide FDCs with important cytokine stimuli such as membranous lymphotoxin 
(LT) α1β2 and tumour-necrosis factor (TNF) α which maintain FDCs in their differentiated 
state (Mackay and Browning 1998). The absence of FDCs, that can be secondary to the 
absence of B cells or LTα1β2 and TNFα signalling, delays neuroinvasion and reduces 
disease susceptibility (Mabbott, Young et al. 2003) (Mabbott, Mackay et al. 2000) 
(Montrasio, Frigg et al. 2000) (Bruce, Brown et al. 2000). 
Depending on the host and the prion strain, the magnitude and duration of LRT 
involvement can vary considerably. In BSE, the prion titre in lymphoid tissue is typically 
low, and BSE is considered a neurotropic prion strain (Wells, Hawkins et al. 1998). 
vCJD, CWD, and many strains of scrapie, are lymphotropic (Aguzzi and Sigurdson 
2004) and infectivity is detected at high levels both in the CNS and the LRT. Infectivity 
was detected in the tonsils of vCJD infected individuals (Wadsworth, Joiner et al. 2001), 
opening the way to a premortem diagnostic tool. However this finding also raises the 
concern of transmission of vCJD through surgical or diagnostic procedures. 
Although prion accumulation in the secondary lymphoid organs may reach levels similar 
to those found in the CNS of end stage prion infected animals (Madec, Groschup et al. 
2000), this process occurs without apparent damage to these organs. 
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 Neuroinvasion 
 
Neuroinvasion describes the process by which prions enter the CNS following peripheral 
entry in the organism. The exact mechanisms involved remain unclear, but the 
autonomic nervous system seems to play an important role in this process, as 
sympathectomy delays prion disease onset upon intra-peritoneal (i.p.) inoculation 
(Glatzel, Heppner et al. 2001). Moreover, reduction of the relative distance between 
FDCs and sympathetic nerves was shown to accelerate prion pathogenesis (Prinz, 
Heikenwalder et al. 2003). Once prions reach the spinal cord, they spread in both 
anterograde and retrograde directions (Beekes, Baldauf et al. 1996). Two hypothesis 
have been formulated to explain the mechanisms involved in prion axonal transport 
(Heikenwalder, Julius et al. 2007), but experimental data are missing to formally prove 
any of them.  
 
Peripheral involvement in sporadic CJD 
 
sCJD, the most frequent human prion disease is thought to result from PrPSc formation 
within the CNS. However, infectivity was also detectable in peripheral organs of sCJD 
patients, such as lymphoid tissue and muscle (Aguzzi and Sigurdson 2004) (Glatzel, 
Abela et al. 2003). These findings suggest that although a disease of the CNS, the 
presence of infectivity in peripheral organs must be taken into account when biosafety 
issues are discussed. 
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3.4 Mechanisms of neurodegeneration 
 
The mechanisms leading to neuronal death in prion diseases are unknown. The 
absence of neurodegeneration in Prnp0/0 mice argues strongly against neurotoxicity 
resulting from loss of function of PrPC (Bueler, Fischer et al. 1992). Moreover, targeted 
PrPC depletion in neurons of a fully developed mouse brain fails to induce a phenotype, 
ruling out acute loss of PrPC as the cause of neurodegeneration in prion diseases  
(Mallucci, Ratte et al. 2002). However, the physiological function of PrPC may be 
revealed in a pathological situation only. 
It is tempting to postulate that PrPSc, the misfolded, PK resistant, and amyloidogenic 
isoform of PrPC is toxic and that its accumulation is responsible for neuronal cell death. 
Supporting this hypothesis is the spatio-temporal correlation between the deposition of 
PrPSc in the brain and the appearance of neuropathological changes.  PrPSc deposition 
typically appears prior to spongiosis and astrogliosis, which eventually develop in close 
vicinity to PrPSc (Jeffrey, Martin et al. 2001) (Williams, Lucassen et al. 1997) (Jendroska, 
Heinzel et al. 1991) (DeArmond, Mobley et al. 1987). However, a correlation is not 
always present and individual areas of the brain with strong PrPSc immunostaining but 
little or no neuropathological changes can be found (Budka 2003) (Hayward, Bell et al. 
1994) (Parchi, Castellani et al. 1995).  
Neurograft experiments have shown that PrPSc accumulation in the extracellular space is 
not toxic in the absence of PrPC.  Prnp0/0 mice grafted with PrPC-expressing embryonic 
neurons, and subsequently intracerebrally challenged with prions, accumulate 
substantial amounts of PrPSc in the graft and the adjacent Prnp0/0 host tissue. While the 
graft undergoes typical spongiform degeneration, the adjacent Prnp0/0 tissue in contact 
with PrPSc does not undergo neuropathological changes (Brandner, Isenmann et al. 
1996). This suggests that PrPSc deposited extracellularily is not toxic to neurons in itself, 
but that neurodegeneration is instead the consequence of PrPSc formation within or at 
the surface of cells.   
Neuronal depletion of PrPC during the course of prion disease prevents clinical disease 
and reverses spongiosis, even though PrPSc levels in the brain remain high due to 
continuous production of PrPSc by astrocytes (Mallucci, Dickinson et al. 2003).  Also, 
wild-type mice inoculated with hamster prion strain Sc237 propagate mouse-adapted 
prions but do not develop a clinical disease. The propagation occurs slowly, but prion 
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titres seen in end-stage conventional clinical disease are eventually reached. Second 
passage of these prions in mice or hamsters results in conventional transmission with 
short incubation periods and 100% lethality (Hill, Joiner et al. 2000).  
More recently, transgenic mice expressing an anchorless version of  PrPC lacking the 
GPI signal and hence secreted in the extracellular space were shown to accumulate 
PrPSc plaques without developing clinical signs (Chesebro, Trifilo et al. 2005).  
Taken together, these findings support a dissociation between PrPSc accumulation and 
toxicity, and indicate that molecules other than PrPSc such as intermediates in the prion 
replication process could be responsible for prion-induced neurodegeneration (Cohen, 
Pan et al. 1994). 
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4. Neurotoxicity associated with PrPC deletion mutants and Doppel 
overexpression 
 
 
4.1. Prnp knock-out mice and the discovery of Doppel 
 
Doppel is a paralog of PrPC discovered incidentally in 1999 following the generation of 
different Prnp knock-out (Prnp0/0 ) mice and the development of a phenotype in some but 
not all lines. Several Prnp0/0 mouse lines have been generated in an attempt to elucidate 
the physiological function of PrPC. Two lines, called Zürich I (ZHI) (Bueler, Fischer et al. 
1992) and Edinburgh (Edbg) (Manson, Clarke et al. 1994) are healthy except for minor 
electrophysiological (Collinge, Whittington et al. 1994) and circadian rhythm (Tobler, 
Gaus et al. 1996) anomalies. A peripheral  demyelinating neuropathy is also observed in 
aged mice  (Bueler, Fischer et al. 1992). Three other Prnp0/0 lines develop cerebellar 
Purkinje cell degeneration (Sakaguchi, Katamine et al. 1996) (Rossi, Cozzio et al. 2001) 
(Moore, Lee et al. 1999) leading to ataxia in aged mice. The phenotype is rescued by 
co-expression of Prnp, suggesting initially that it is a consequence of the absence of 
PrPC (Sakaguchi, Katamine et al. 1996) (Moore, Lee et al. 1999) (Rossi, Cozzio et al. 
2001). The absence or presence of phenotype parallels the strategy used to generate 
the Prnp0/0 lines. ZHI and Edbg were generated by replacing parts of the Prnp open 
reading frame (ORF) with a neomycin phosphotransferase gene (figure 7a). In the case 
of a third Prnp0/0 line, called  Nagasaki (Ngsk), 0.9kb of intron 2, the 5’ non coding region 
and 0.45kb of the 3’non-coding region were deleted in addition to the Prnp ORF 
(Sakaguchi, Katamine et al.1996) (figure 7a).  The phenotype observed in the Ngsk line 
was independently confirmed by two additional  knock-out lines, Zürich II (ZHII) and 
Rcm0, in which the Prnp ORF and its flanking regions were replaced by a lox sequence 
and a hypoxanthine phosphoribosyltransferase (HPRT) cassette, respectively (Moore, 
Lee et al. 1999) (Rossi, Cozzio et al. 2001) (figure 7a). This suggested that the 
Nagasaki phenotype is not due to the absence of PrPC, but rather to the cloning strategy.  
Sequence analysis of a cosmid containing Prnp revealed an ORF located 16kb 
downstream of Prnp, now known to code for Doppel (Dpl, for downstream of the Prnp 
locus, figure 7b). In the Ngsk, ZHII and Rcm0 lines, the deletion of intron 2 (including its 
splicing acceptor) leads to an intergenic splicing event, placing the Dpl locus under the 
control of the endogenous Prnp promoter (figure 7c). This intergenic splicing event is 
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also detected at very low levels in wild-type mice, but is greatly enhanced by the 
absence of the intron 2 splice acceptor (Moore, Lee et al. 1999) (Behrens and Aguzzi 
2002) .  
In contrast to PrPC, Dpl is expressed at very low levels in the CNS of wild-type mice. In 
the Ngsk, ZHII and Rcm0 mice, Doppel gene (Prnd) mRNA is upregulated (Moore, Lee 
et al. 1999) (Lu, Wang et al. 2000) (Mo, Moore et al. 2001) (Silverman, Qin et al. 2000), 
leading to overproduction of Dpl in the brain of these Prnp0/0 lines. An inverse correlation 
links Prnd mRNA levels to the onset of ataxia and increasing Prnd levels accelerate 
disease progression (Rossi, Cozzio et al. 2001). Deletion of Prnd from the ZHII mice 
abolishes the Nagasaki phenotype (Genoud, Behrens et al. 2004), confirming that the 
ectopic expression of Dpl in the CNS rather than the absence of PrPC is responsible for 
the Purkinje cell loss. 
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Figure 7 
Prnp Knock-out strategies and their consequences. A Various strategies used to target Prnp by 
homologous recombination. The black boxes represent PrP ORFs; white boxes, non-coding Prnp regions; 
grey boxes, inserted sequences; dotted line, deleted regions; neo, neomycin phosphotransferase; HPRT, 
hypoxanthine phosphoribosyltransferase; loxP (black arrowhead), a 34-bp recombination site from phage 
P1. B Coding and non-coding exons of Prnp, Prnd and intergenic exons of unknown function. C Exon 
skipping leads to expression of Doppel under the direction of the Prnp promoter. Deletion of the splice 
receptor site upstream of the third Prnp exon entails the formation of several chimeric mRNAs comprising 
the first two exons of Prnp, which are spliced directly or indirectly to the Dpl-encoding exon14. From 
Weissamnn et  al., Br Med Bull, 2003. 
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Figure 8 
Structural features of the cellular prion protein, Doppel, and the chimeric protein Dpl_PrP. A 
Primary structure of the cellular prion protein.The numbers describe the position of the respective amino 
acids. SS (yellow) indicates the signal sequence; CC1 (pink) represents the charged cluster 1; OR (light 
blue) designates the octarepeat region; CC2 (dark blue) represents the charged cluster 2 and HC 
(orange) the hydrophobic core. The beta sheets are depicted in green and the alpha helices in red. S-S 
indicates the disulphide bridge. GPI denotes the membrane anchorage region. B Primary structure of 
Doppel. The numbers describe the position of the respective amino acids. SS (yellow) indicates the signal 
sequence. The beta sheets are depicted in green and the alpha helices in purple. S-S indicates the 
disulphide bridges. GPI denotes the membrane anchorage region. C Primary structure of a chimeric 
protein resulting from the fusion of Doppel with the first 134 amino acids of the prion protein. The numbers 
describe the position of the respective amino acids. SS (yellow) indicates the signal sequence; CC1 (pink) 
represents the charged cluster 1; OR (light blue) designates the octarepeat region; CC2 (dark blue) 
represents the charged cluster 2 and HC (orange) the hydrophobic core. The beta sheets are depicted in 
green and the alpha helices in purple. S-S indicates the disulphide bridges. GPI denotes the membrane 
anchorage region.  
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4.2 The neurotoxicity of Doppel and amino-truncated versions of PrPC 
 
The Dpl gene Prnd has been identified in many vertebrates including mouse (Moore, 
Lee et al. 1999), cattle,  sheep (Tranulis, Espenes et al. 2001) and human (Moore, Lee 
et al. 1999) (Peoc'h, Guerin et al. 2000) and is highly conserved among mammals  
(Tranulis, Espenes et al. 2001). Prnp and Prnd bare no nucleic acid sequence homology 
and share only 24% identity in protein sequence (Mo, Moore et al. 2001) (Mastrangelo 
and Westaway 2001). However, the tertiary structure of Dpl is very similar to that of the 
carboxy-terminal two-thirds of PrPC (Riek and Luhrs 2003). As PrPC, Dpl is a GPI 
anchored protein harbouring 3 α-helices, two anti-parallel β-sheets and two facultative 
N-glycosylation sites (Mo, Moore et al. 2001). Dpl lacks a counterpart to the flexible N-
terminal segment of PrPC (Mastrangelo and Westaway 2001) (figure 8b).  
The expression pattern of Dpl differs greatly from that of PrPC. It is expressed at high 
levels in testis, at lower levels in other peripheral organs and at very low levels in the 
adult CNS (Moore, Lee et al. 1999). The generation of a Prnd knock-out mouse (Prnd 0/0) 
led to the identification of Dpl as a critical regulator of acrosome function in male 
gametogenesis (Behrens, Genoud et al. 2002).  
There is no evidence that Dpl can become misfolded in presence of PrPSc. Indeed, in 
mice defective or overexpressing Dpl, neither the time course of prion disease nor the 
generation of PrPSc are significantly modified (Tuzi, Gall et al. 2002). 
A neurotoxic phenotype similar to the one elicited by overexpression of Dpl in the CNS 
is observed in ZHI mice transgenically expressing amino-truncated versions of PrPC. 
These mutants, called PrPΔE  (Δ residue 32-121 ) and  PrPΔF (Δ residue 32-134 ) and 
collectively referred to as  PrPΔN, harbour deletions including the octarepeat region and 
extending into the highly conserved hydrophobic core. While both Dpl overexpression in 
the CNS and transgenic expression of PrPΔN in ZHI mice lead to cerebellar 
neurodegeneration, cerebellar cortical neurons, and not Purkinje cells are the target of 
PrPΔN induced neurotoxicity.  The absence of toxicity of PrPΔN in Purkinje cells can be 
explained by the vector driving the transgene expression (Fischer, Rulicke et al. 1996), 
which is not active in Purkinje cells (Shmerling, Hegyi et al. 1998) (Rossi, Cozzio et al. 
2001). This is supported by the fact that targeted expression of PrPΔF to Purkinje cells 
leads to degeneration of these cells (Flechsig, Hegyi et al. 2003).  
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As in the case of Dpl overexpression in the CNS, the neurotoxicity induced by PrPΔN is 
abolished by co-expression of wild-type PrPC (Flechsig and Weissmann 2004) (Flechsig, 
Shmerling et al. 2000).  
Transgenic expression of two PrP  mutants with an intact octarepeat region but 
harbouring truncations in the central domain leads to a highly neurotoxic phenotype. The 
neurotoxicity arising from PrPΔ105-125 (Li, Christensen et al. 2007) expression is similar to 
the one elicited by PrPΔE and PrPΔF, yet much stronger. Indeed, supraphysiological levels 
of wild-type  PrPC are needed to reduce the cortical neuron death and attenuate the 
leukoencephalopathy, but fail to rescue the phenotype completely (Li, Christensen et al. 
2007). The expression of PrPΔCD (Δ 94-133) (Baumann, Tolnay et al. 2007) which lacks 
the whole central domain, elicits a predominantly white matter disease, with central and 
peripheral axonomyelinic degeneration. Supraphysiological levels of PrPC are required 
to abolish the phenotype.  
All proteins eliciting a neurotoxic phenotype bear deletions extending into the 
hydrophobic core, identifying the disruption of this highly conserved domain as 
determinant in the development of a neurotoxic phenotype (Shmerling, Hegyi et al. 
1998). The phenotype they elicit is rescued by coexpression of various levels of full-
length PrPC, indicating that a same molecular mechanism underlies their neurotoxicity.  
It is suggested that PrPC interacts with a yet unknown receptor (PrPR) to deliver an 
essential signal. Neurotoxicity arises from the binding of  PrP-like molecules Dpl or 
PrPΔN to PrPR without delivery of the signal (Weissmann and Aguzzi 1999). Confusingly, 
the expression of a third mutant, PrPΔpHC, which lacks eight residues in the hydrophobic 
core (Δ 114-121) is not intrinsically toxic but exacerbates the phenotype of PrPΔCD while 
attenuating that of PrPΔF. A model taking into account all the mutants discussed here 
has been suggested by Baumann et al (Baumann, Tolnay et al. 2007). However, the 
identification of the hypothetical PrP receptor PrP-R is required to verify this model. 
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Figure 9 
Structural features of the cellular prion protein and the amino-terminal deletion mutants. Primary 
structure of the cellular prion protein including post-translational modifications. The numbers describe the 
position of the respective amino acids. SS (yellow) indicates the signal sequence; CC1 (pink) represents 
the charged cluster 1; OR (light blue) designates the octarepeat region; CC2 (dark blue) represents the 
charged cluster 2 and HC (orange) the hydrophobic core. The beta sheets are depicted in green and the 
alpha helices in red. S-S indicates the disulphide bridge. GPI denotes the membrane anchorage region. 
Ref. a: (Fischer, Rulicke et al. 1996). Ref. b : (Shmerling, Hegyi et al. 1998). Ref. c:  (Flechsig, Shmerling 
et al. 2000). Ref. d: (E. Flechsig). Ref. f: (Baumann, Tolnay et al. 2007). Ref.g: (Baumann). Ref. h: (Li, 
Christensen et al. 2007) 
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Figure 10 
A model for the positive and negative effects of PrPC and its variants. A PrP (black) consists of a 
globular C-terminal domain (hexagon) and an N-terminal flexible tail (arch) encompassing the ORs (circle). 
The model rests on the following assumptions: (1) PrPC activates a hitherto unidentified receptor (PrPR), 
which transmits myelin maintenance signals (flashes); (2) in the absence of PrPC, PrPR exerts some 
residual activity, either constitutively or by recruiting a surrogate ligand; (3) the activity of PrPC and its 
mutants requires homo- or heterodimerization, and induces dimerization of PrPR; and (4) PrP dimers 
containing PrPΔCD or PrPΔF trap PrPR in an inactive dominant-negative state. Finally, (5) the OR region 
stabilizes the interaction between PrP and PrPR, but does not contribute directly to signalling. B By 
increasing complex affinity to PrPR through its ORs, PrPΔpHC may displace PrPΔF homodimers, thereby 
ameliorating the phenotype of compound PrPΔFΔpHC transgenic mice. However, as PrPΔCD also contains 
ORs, it may more efficiently compete with PrPΔpHC for PrPR and thus prevents any phenotypic 
improvement. 
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II. Generation of a transgenic mouse to study the role of the 
flexible amino-terminal domain in the physiological function 
of PrPC 
 
 
1. Summary and outline of the study 
 
 
Mice devoid of PrPC (Prnp0/0) develop normally and fail to exhibit a phenotype in the 
CNS. However, transgenic mice expressing amino-truncated versions of PrPC with 
deletions extending into the hydrophobic core (collectively termed PrPΔN) suffer from 
neurodegeneration, suggesting a role for this domain in a survival pathway. One of such 
mutants, PrPΔCD, is particularly toxic, leading to death of Prnp0/0 mice around postnatal 
day 25.  
Doppel, a protein structurally similar to the carboxy-terminal domain of PrPC (figure 8b) 
and physiologically expressed in the testis, is toxic when expressed in the CNS, eliciting 
a phenotype similar to that induced by PrPΔN expression.  
In both cases, neurodegeneration is rescued by co-expression of full-length PrPC, 
suggesting all proteins are involved in the same pathway and compete for interaction 
with a yet unknown receptor (PrPR).   
A chimeric protein consisting of Doppel fused to the amino-terminal domain of PrPC, 
termed Dpl_PrP (figure 8c), is not toxic and can rescue the neurodegeneration induced 
by PrPΔN (Baumann et al, manuscript in preparation). A similar construct was recently 
shown to rescue the neurotoxicity of Doppel expression in the CNS (Yoshikawa, 
Yamaguchi et al. 2008). These findings confirm the essential role of the amino-terminus 
of PrPC in conveying the activity of the full-length protein.  
To understand the contribution of the globular domain to the physiological activity of the 
full-length protein, we generated a transgenic mouse expressing a redacted version of 
the prion protein, lacking the entire carboxy-domain (PrPΔ141-231). 
We crossed this mouse with two transgenic lines expressing PrPΔCD, and show that co-
expression of PrPΔ141-231 does not modify the toxic phenotype induced by PrPΔCD, 
although both proteins are expressed in the same compartment (lipid rafts) and at 
similar levels.  
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However, the results of the rescue experiments must be interpreted with caution. Indeed, 
while a low amount of a toxic mutant (PrPΔCD) with a potentially high affinity for PrPR 
induces a phenotype, the co-expression of an equimolar amount of a protein devoid of 
the globular domain might not suffice to compete for interaction with PrPR. The absence 
of rescue may thus rather be due to the reduced affinity of PrPΔ141-231 for PrPR and an 
increased molar ratio of PrPΔ141-231 to PrPΔCD may be required to compete for interaction 
with PrPR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
2. Results 
 
 
2.1 Expression of the transgene in two different murine neuronal cell lines 
gives rise to a stable protein located in lipid rafts 
 
2.1.1 Generation of the transgene 
 
To investigate the contribution of the carboxy-domain of PrPC to the physiological 
function of the full-length protein, we generated a transgene coding for a truncated 
murine PrPC variant lacking the carboxy-terminal globular domain. To direct the protein 
to the same subcellular compartment as the full-length protein, we fused the amino-
terminal domain to the GPI anchor signal of PrPC. The resulting protein, called PrPΔ141-
231, consists of the first 140 amino acids of PrPC directly linked to the last 23 amino acids 
of the full length polypeptide which are replaced, in the mature protein, by a GPI anchor 
(figure 11).  
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Figure 11 
Primary structure of murine PrPC. The numbers describe the positions of the amino-acids. SS (yellow) 
designates the signal sequence; CC1 (pink) represents the charged cluster 1; OR (purple) the four 
octarepeats; CC2 (dark blue) the charged cluster 2; HC (orange) the hydrophobic core; β (green) the two 
β-sheets and α (red) the three α-helices. GPI anchor (glycosyl-phosphatidyl-inositol anchor).The N-
terminus of PrPC spans from amino-acid 1 to 140. It includes a short β-sheet (amino-acids 128-131) within 
the hydrophobic core. The structured C-terminal domain starts at the first α-helix and ends at amino-acid 
231, were the GPI anchor is added. Two facultative N-glycosylation sites exist (amino-acids 181 and 197), 
giving rise to three PrPC species: un-, mono- and di-glycosylated PrPC. The anti-PrP antibodies POM2, 
POM3 and POM11 are illustrated in blue. The anti-PrP antibody POM1 (illustrated in red) recognizes an 
epitope within the first α-helix. A Full length murine PrP consists of 231 amino-acids. B PrPΔ141-231: the first 
140 amino-acids of PrP are directly linked to the GPI recognition site. 
 
 
2.1.2 Cloning strategy 
 
The strategy used for the construction of the transgene is described in the materials and 
methods section.  Briefly, total mouse brain cDNA was used as a template, and 
appropriately designed primers were employed to amplify and fuse the amino-terminus 
of full length PrPC with the GPI signal sequence of the protein.  
  
 
2.1.3 Expression of the transgene in two neuronal cell lines 
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Wild-type PrPC and PrPΔ141-231 sequences were inserted into an expression plasmid 
(pBMN). The resulting plasmids were transfected into Hpl and N2a cells. The Hpl cell 
line is derived from hippocampal neurons isolated from Ngsk mice, and hence does not 
express Prnp, while the neuroblastoma-derived cell line N2a does. 
Full length unglycosylated PrPC is a 25 kD protein consisting of 209 amino-acids (figure 
12, lane 6). PrPΔ141-231 consists of 118 amino acids and lacks the 2 facultative N-
glycosylation sites that are located in the globular carboxy-terminus of full length PrPC. 
We found that PrPΔ141-231 is expressed as an unglycosylated 15kD protein in Hpl (figure 
12, lane 1 and 4). To assess the integrity of PrPΔ141-231, we verified the presence of 
epitopes of three amino-terminal anti-PrP antibodies (POM11, POM3 and POM2, figure 
11). All epitopes were present in PrPΔ141−231 (data not shown). However, these findings 
cannot exclude a truncation of the protein amino-terminally to the OR region (POM12 
epitope; figure 11) or carboxy-terminally to the central domain (POM3 epitope; figure 11).  
The presence of the GPI anchor was assessed by comparing the electrophoresis 
mobility of PrPΔ141−231 with that of an anchorless version of the same protein (called 
sPrPΔ141−231 for secreted PrPΔ141−231) on a SDS-PAGE. The slight difference in the 
electrophoresis mobility of the two proteins suggested the presence of a GPI anchor in 
PrPΔ141−231 (figure 13).  
In N2a cells, expression of the transgene gave rise to the same 15kD band and an 
additional, higher molecular weight band (figure 13, lane 2). The identity of this second 
band is unknown, but the two species do not correspond to a GPI anchor plus and 
minus version of the same protein, since sPrPΔ141−231 runs at a lower molecular weight on 
a SDS-PAGE  (figure 13, lane 4). 
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Figure 12 
Expression of PrPΔ141-231 in Hpl cells gives rise to a 15kD protein. Lane 1 and 4, cell lysate of Hpl cells 
transfected with PrPΔ141-231. Lane 2 and 5 cell lysate of Hpl cells trasfected with the empty vector. Lane 3 
and 6, cell lysate of Hpl cells transfected with wild-type PrP. Lane 4 to 6: cell lysate subjected to peptide-
N-glycanase (PNGase) digestion. Western blot probed with POM11 (see figure 11). 
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Figure 13 
Expression of PrPΔ141-231 in N2a cells. Lane 1: cell lysate of N2a cells transfected with the empty vector. 
The endogenous PrPC is seen between 25 and 37kD. Lane 2: cell lysate of N2a cells transfected with the 
PrPΔ141-231 construct. Lane 3: cell lysate of untransfected Hpl cells. Lane 4: cell lysate of N2a cells 
transfected with sPrPΔ141-231. Western blot probed with POM11 (see figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.4 PrP141−231 is located in lipid rafts in Hpl cells  
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The buoyancy of PrPΔ141−231 in a step density gradient centrifugation was similar to that of 
PrPC and flotillin, indicating that PrPΔ141−231 resides in lipid rafts of Hpl cells (figure 14).  
These results show that a PrPC variant lacking most of its structured domain can be 
successfully expressed in vitro, and that this protein is located in similar membrane 
microdomains as the full length protein.  
 
 
 
 
 
Figure 15 
PrPΔ141-231 colocalizes with flotillin in lipid rafts. Left panel: Hpl cells transfected with the PrPΔ141-231 
sequence. Right panel: Hpl transfected with PrP wild-type sequence. The lower blots were probed with 
POM2 (see figure 11) and the upper blots with an anti-flotillin antibody.  
Fractions 3 to 5 (F3-F5): 5% Optiprep. Fractions 6 to 8 (F6-8): 30% Optiprep. Fractions 9 to 11 (F9-11): 
40% Optiprep. 
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2.2 Generation of a transgenic mouse expressing PrPΔ141-231 
 
2.2.1 The expression vector 
 
Based on the results obtained in the cell culture experiments, we proceeded to the 
generation of a transgenic mouse expressing PrPΔ141−231. 
The vector used to drive the expression of the transgene in vivo is the “half genomic 
vector” (Fisher 1996). It encompasses the entire murine Prnp locus, with 6 kb and 2.2 kb 
of 5’ and 3’ untranslated sequences, respectively. The second intron of Prnp is deleted, 
fusing exons 2 and 3 (figure 16). The vector directs orthoptic expression of Prnp to 
almost all cell types in which PrPC is expressed. One notable exception are cerebellar 
Purkinje cells. 
The open reading frame (ORF) of PrPC was replaced by that of PrPΔ141−231 in the half-
genomic construct. The cloning strategy is described in the materials and methods 
section.  
 
 
Figure 16 
Murine Prnp and the half-genomic construct. Exons are represented as boxes. Exon 1 (blue box) is 
separated from exon 2 (green box) by intron 1. A. In Prnp, intron 2 separates exon 2 from exon 3 (red). B. 
In the half-genomic construct (phgPrP), intron 2 is deleted and exon 2 and 3 are fused.  
 56 
 
2.2.2 Pronuclei microinjections 
 
The half-genomic construct containing the PrPΔ141−231 ORF was injected into pronuclei of 
Prnp+/+ mice in the laboratory of Thomas Rülicke in Vienna.  
Sixty potential founders were screened by tail PCR for the presence of the transgene. 
Fourteen mice were transgene positive. Three transgenic lines (tg155, tg157 and tg177) 
were selected on the basis of the protein expression level of the transgene in the CNS 
(figure 17). The highest expresser line, tg157, was unfortunately lost. The founder and 
its positive offspring died before further analysis could be performed. 
The two remaining lines (tg155 and tg177) were crossed with Prnp0/0 mice to obtain 
transgenic positive offspring on a Prnp0/0 background. Both male and female offspring 
were born with Mendelian frequencies and had a normal life span.  
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Figure 17 
Transgene expression analysis in the brain of six transgenic lines. Western blot of brain 
homogenate of six transgenic lines (tg152, tg155, tg157, tg158, tg177 and tg180) on a Prnp+/- background, 
and Prnp0/0 and wild-type (wt) controls. A Blot probed with POM11, an amino-terminal antibody (see figure 
11). The wild-type allele gives rise to three bands between 37 and 25 kD (di-, mon-, and unglycosylated 
PrPC). The transgene gives rise to two bands around 15kD B Duplicate of A, probed with POM1, a 
carboxy-terminal antibody (see figure 11).  POM1 does not recognise the transgene, but detects the wild-
type allele and the carboxy-terminal cleavage products of PrPC, amongst which unglycosylated C1 (see 
figure 5), which runs at about 15 kD. 
 
 
2.2.3 The transgene copy number in line tg155 and tg158 
 
Southern blot analysis was performed for line tg155 and tg158 and revealed a 
transgene copy number of 12 and 18, respectively (figure 18 C). The protein expression 
of tg158 being low, the line was eliminated. 
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Figure 18 
Determination of transgene copy number in two transgenic lines. A Transgene (half-genomic) 
displaying EcoRI restriction sites. Digestion with EcoRI gives rise to a 2792bp fragment. B Murine Prnp 
displaying EcoRI restriction sites. Digestion with EcoRI gives rise to a 2148bp  fragment. C Southern blot 
of two transgenic lines tg155 and tg177. Lane 1 and 2: tg155 on a Prnp+/- background. Lane 3: empty. 
Lane 4 and 5: tg158 on a Prnp+/- background. Lane 6 and 7: wild-type. Lane 8 and 9: Prnp0/0, which does 
not anneal with the probe. The wild-type allele (2148bp) is indicated with a blue arrowhead and the 
transgene (2792bp) with a red arrowhead.  
 
 
2.2.4 PrPΔ141-231 expression in the brain of tg155 and tg177 is low 
 
Expression of the transgene in vivo gave rise to two bands migrating at 15 and 16kD in 
an SDS-PAGE (figure 19), similarly to what was seen in N2a cells transfected with the 
PrPΔ141-231 construct (figure 13). Both bands were detectable with three amino-terminal 
anti-PrP antibodies POM2, POM3 and POM11 (data not shown). The two bands were 
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also detectable in primary cortical neurons isolated from E 15.5 tg155 mice (data not 
shown). 
 
 
Figure 19  
Transgene expression analysis in the brain of tg155. Western blot of brain homogenate of Prnp0/0 
(lane 1), Prnp0/0 tg155 (lane 2) and wild-type (lane 3) mice. Blot probed with POM2, an amino-terminal 
antibody (see figure 11). The wild-type allele gives rise to three bands between 37 and 25 kD (di-, mon-, 
and unglycosylated PrPC). The transgene gives rise to two bands around 15kD. An unspecific band is 
seen at 37kD in all three samples including the Prnp0/0 control. 
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2.2.5 PrPΔ141-231 is located in lipid rafts in the CNS 
 
In order to be able to observe a potential rescue of the neurotoxic phenotype seen in 
transgenic mice expressing PrPΔN variants, PrPΔ141-231 has to be localized in the same 
subcellular compartment as PrPΔN and PrPC.  
We found that both bands resulting from the expression of the PrPΔ141-231 construct were 
localized in lipid rafts in the mouse brain. However, while PrPC is mostly recovered in 
fraction 4, PrPΔ141-231 is detected in fraction 5, suggesting the two proteins could be 
located in different types of lipid rafts (figure 20). 
 
 
 
Figure 20 
PrPΔ141-231 colocalizes with flotillin in lipid rafts. Left panel: Brain homogenate of tg155 on a Prnp-/- 
background. Right panel: Brain homogenate of a wild-type mouse. The lower blots were probed with 
POM11 (see figure 11) and the upper blots with an anti-flotillin antibody.  
Fractions 3 to 5 (F3-F5): 5% Optiprep. Fractions 6 to 8 (F6-8): 30% Optiprep. Fractions 9 to 11 (F9-11): 
40% Optiprep. 
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2.2.6 Quantification of the transgene expression 
 
We compared the expression levels of PrPΔ141-231 to that of endogenous PrPC in the 
brain of wild-type mice by quantitative Western blotting. Serial dilutions of wild-type brain 
homogenate were blotted (figure 21A), and the relative expression levels of the two 
molecules were calculated from calibration curves obtained by direct acquisition of 
chemiluminescence (figure 21B). In total brain homogenate, we found that tg155 and 
tg177 expressed PrPΔ141-231 at a level corresponding to 7% and 9% respectively of a 
Prnp+/+ mouse (Figure 21). 
Quantification of RNA expression revealed that the relative transcript copies of tg155 to 
wild-type was 18 times higher (figure 22), suggesting that PrPΔ141-231 is less stable than 
the full length protein. 
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Figure 21 
Quantification of PrPΔ141-231 in the brain of tg155 and tg177 compared to PrPC in wild-type mouse 
brain. Upper panel: western blot probed with POM11 (figure 11). Lane 1: 20ug protein of a tg155 (Prnp-/- 
background) brain homogenate. Lane 2: 20ug protein of a tg177 (Prnp-/- background) brain homogenate. 
Lane 3: 20ug protein of a Prnp-/- brain homogenate. Lane 4: 20ug protein of a Prnp+/+ brain homogenate. 
Lane 5-9: serial 1:2 dilution starting with the amount of protein in lane 4. Lower panel  
 
 
 
 
 
 
 
Figure 22 
Brain RNA levels of PrPΔ141-231 in tg155 compared to the RNA levels of PrPC in a wild-type mouse 
brain. The RNA levels of PrP Δ141-231 are 18 times higher than that of PrPC in a wild-type mouse brain, 
paralleling the transgene copy number in tg155. 
 
 
 
 
2.2.7  PrPΔ141-231 has a reduced half-life in vivo 
 
To verify if the discrepancy between the high RNA levels and the relatively low protein 
levels in the brain of tg155 and tg177 mice were due to a decreased stability of PrP Δ141-
231, we measured the half-life of PrP Δ141-231 in organotypic slice cultures of tg155 
cerebella. We found that the half-life of PrP Δ141-231 is of about 30 minutes (figure 23), 
while that of PrPC using the same set-up is of 8 hours (data communicated by Anna-
Maria Callela). However, the antibody used for the measurement of the half-life of the 
full-length protein (POM1) has a much higher affinity for its ligand than POM12, the 
 63 
antibody used in the case of PrP Δ141-231, which does not allow a direct comparison of the 
two values. 
 
 
 
 
 
Figure 23 
Pulse chase experiment in organotypic slice cultures of mouse cerebella. A Left panel: POM12 
immunoprecipitation of cerebellar slice lysate from tg155 mice (lane 1, 3, 4, 5 and 6) and Prnp0/0 mice 
(lane 2).  Lane 1 and 2: pulse. Lane 3, 4, 5 and 6: chase of 15 minutes, 30 minutes, 1 hour and 2 hours, 
respectively. Right panel: western blot control of the input. B Left panel: immunoprecipitation of cerebellar 
slice lysate using POM1 from wild-type mice (lane 1, 3, 4, 5 and 6) and Prnp-/- mice (lane 2).  Lane 1 and 
2: pulse. Lane 3, 4, 5 and 6: chase of 4, 8, 24 and 36 hours, respectively. Right panel: western blot control 
of the input. 
 
 
 
2.2.8 Transgenic mice tg155 and tg177 have a normal life expectancy and do not 
develop a spontaneous phenotype 
 
Both transgenic lines expressing PrPΔ141-231 developed and reproduced normally and did 
not present a phenotype in adulthood. Transgenic positive Prnp0/0 mice were sacrificed 
at 20 weeks of age for histological analysis. We did not find any anomalies in the 
cerebellum (figure 24A), cortex (figure 24B upper panels) and hippocampus (figure 24B 
lower panels), correlating with absence of phenotype in these mice.  
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Figure 24 
Histological analysis of the CNS of Prnp0/0 tg155 mice. A Cerebellum of 20 weeks old Prnp0/0 tg155 
mouse. Left panels, H-E staining. Right panels, GFAP staining. B Upper panel: cerebral cortex of 20 
weeks old Prnp0/0 tg155 mouse. Left panel, H-E staining. Right panel, GFAP staining. Lower panels : 
hippocampus of 20 weeks old Prnp0/0 tg155 mouse. Left panel, H-E staining. Right panel, GFAP staining. 
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2.3 Expression of PrPΔ141-231 fails to rescue the phenotype elicited by the 
expression of PrPΔCD 
 
 
2.3.1 Expression level comparison 
 
We compared the brain expression level of PrPΔ141-231 in tg155 and tg177 mice with that 
of PrPΔCD in two transgenic lines, tg1046 and tg1050 (Baumann, Tolnay et al. 2007). We 
found that the expression level of PrPΔCD in line tg1046 is comparable to that of PrPΔ141-
231 in tg155 and tg177, while PrPΔCD is expressed six times more in tg1050 (figure 25). 
 
 
 
Figure 25 
PrPΔ141-231 and PrPΔCD expression in the brain of transgenic animals. Western blot probed with POM11 
(see figure 11). 20ug of brain homogenate per lane. Lane 1: tg155; lane 2: tg177; lane 3: Prnp0/0 lane 4: 
tg1046; lane 5: tg1050.  
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2.3.2 Rescue experiment: crossing tg155 with tg1046 and tg1050 
 
In order to assess the ability of PrPΔ141−231 to convey the function of full-length PrPC, we 
crossed Prnp0/0 tg155 mice with Prnp0/0 tg1046 and Prnp0/0 tg1050 mice.  
In the absence of a wild-type allele, Prnp0/0 tg1046 mice die 25 days after birth. The 
presence of one allele of wild-type PrPC suffices to rescue completely the phenotype, 
and Prnp+/- tg1046 mice have a normal lifespan (Baumann, Tolnay et al. 2007). 
The expression level of PrPΔCD in tg1050 mice is six times higher than in tg1046 mice. 
Accordingly, the neurotoxic phenotype is much stronger and leads to perinatal death of 
Prnp0/0 mice. Supraphysiological levels of PrPC are required to partially rescue the 
phenotype, and the tg1050 line is thus kept on a tga20 (PrPC overexpressing transgene) 
hemizygous background, in order to allow survival and reproduction of PrPΔCD 
expressing mice (Baumann, Tolnay et al. 2007).  
Double positive Prnp0/0 mice carrying both the PrPΔCD and PrPΔ141−231 alleles, resulting from 
either the tg155 x tg1046 or the tg155 x tg1050 crossing did not survive longer than 
single transgenic mice carrying the PrPΔCD allele only (figure 26A and B), indicating that 
PrPΔ141−231 does not have an impact on the toxic phenotype elicited by PrPΔCD. 
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Figure 26 
Kaplan-Meyer curve of the offspring resulting from breeding of tg155 with two transgenic lines 
expressing PrPΔCD. A tg155 x tg1046. Line tg1046 is kept on a Prnp+/- background. Red triangles are 
Prnp0/0 single positive transgenic mice carrying the PrPΔCD allele; green squares are Prnp0/0 double positive 
transgenic mice carrying both the PrPΔCD and PrPΔ141-231 allele; black triangles are Prnp+/-  single positive 
transgenic mice carrying the PrPΔCD allele; black diamonds are Prnp0/0 mice and black circles are Prnp0/0 
single positive transgenic mice carrying the PrPΔ141-231 allele  B tg155 x tg1050. The tg1050 line is kept on 
a tga20 hemizygous background to allow survival of the transgene positive offspring. Green squares are 
Prnp0/0 double positive transgenic mice carrying both the PrPΔCD and PrPΔ141-231 allele; red triangles are 
Prnp0/0 single positive transgenic mice carrying the PrPΔCD allele; black triangles are  Prnp0/0 double 
positive transgenic mice carrying both the PrPΔCD and tga20 allele. 
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3. Discussion 
 
 
In 1992, the ablation of murine PrPC was shown to have little if any effect in the CNS, 
limiting the use of this model to investigate the function of the protein in vivo (Bueler, 
Fischer et al. 1992). A few years later, Prnp0/0 mice transgenically expressing amino-
truncated PrPC variants were reported to suffer from spontaneous cerebellar 
neurodegeneration which was rescued by co-expression of full length PrPC, opening a new 
avenue to study the physiological function of PrPC (Shmerling, Hegyi et al. 1998). 
The generation of other truncated PrPC variants bearing smaller deletions in their amino-
terminus allowed narrowing down of the region whose disruption leads to 
neurodegeneration. This region, called the hydrophobic core, is highly conserved amongst 
all species expressing PrPC (Baumann, Tolnay et al. 2007) (Li, Christensen et al. 2007). 
The central role of the amino-terminus of PrPC, and in particular of its hydrophobic core in 
the physiological function of the full-length protein was thus established, and the next logical 
question to ask was whether the presence of the amino-terminus was not only necessary 
but also sufficient to convey the function of the full length protein. A first experimental 
approach to address this question was chosen by Baumann et al, who generated a 
chimeric protein by substituting the carboxy-terminus of PrPC with a structural analogue of 
this domain, Doppel. They showed that, not only was this chimeric protein innocuous when 
expressed in the CNS, but it was also able to rescue the phenotype elicited by PrPΔN 
(Baumann et al., manuscript in preparation) (figure 8c). A similar construct was recently 
shown to be able to rescue the toxicity induced by overexpression of Dpl in the CNS 
(Yoshikawa, Yamaguchi et al. 2008). These findings confirmed the central role played by 
the amino-terminus of PrPC in conveying a signal and indicated that while the presence of a 
structured globular domain might be involved in the function of PrPC, the amino acid 
sequence of this domain is not relevant. 
To further address the question of the importance of a globular domain in the function of the 
full-length protein, we generated a redacted version of PrPC consisting solely of its amino-
terminus linked to the GPI anchor signal. 
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Transgene expression gives rise to a stable protein, both in vitro and in vivo 
 
Our first concern was to assess the stability of PrPΔ141-231. A previous study  had reported 
the absence of expression of such a construct in vitro (Muramoto, DeArmond et al. 1997). 
We show that expression both in vitro and in vivo is possible, and that PrPΔ141-231 is located 
in the same subcellular compartment as wild-type PrPC. 
Two lines of evidence indicate that PrPΔ141-231 is not released in the supernatant of 
transfected cells, but rather located in the lipid raft compartment of the cell, were PrPC is 
likely to exert its function. First, the electrophoretic mobility of PrPΔ141-231 expressed in a 
neuronal cell line indicates a higher molecular weight than the secreted version of the same 
protein, consistent with the presence of a GPI anchor in PrPΔ141-231. Second, PrPΔ141-231 co-
localizes with flotillin, a lipid raft protein, after centrifugation in a step density gradient both 
in vitro and in vivo.   
Although the RNA levels of PrPΔ141-231 in the CNS are high, the protein expression is low, 
corresponding to 9% of PrPC expressed in the brain of a wild-type mouse (tg155).  The half-
life of PrPΔ141-231 was estimated to 30 minutes, while that of full length PrPC measured using 
the same settings but different antibodies was estimated to 8 hours, indicating a reduced 
stability of PrPΔ141-231.  
 
The expression of PrPΔ141-231 in vivo does not lead to a phenotype 
  
PrPC variants expressed transgenically can elicit a toxic phenotype either by interfering with 
the normal function of PrPC, as in the case of PrPΔN expression,  or by accumulating in an 
inappropriate cellular compartment (toxic gain-of-function), such as for example cyPrPC, a 
PrPC variant lacking the signal peptide and accumulating in the cytoplasm (Ma, Wollmann 
et al. 2002). According to the model proposed by Baumann et al. (Baumann, Tolnay et al. 
2007), the expression of PrPΔ141-231 is not expected to elicit a phenotype, since it retains the 
putative functional domain of PrPC. Transgenic expression of PrPC variants lacking either 
the second or the third α-helix were reported to suffer from a disorder resembling a 
neuronal storage disease. The truncated prion protein variants were not exported to the cell 
surface and accumulated in the ER (Muramoto, DeArmond et al. 1997). PrPΔ141-231 
expression did not elicit such a toxic gain-of-function in tg155 and tg177, although all three 
helices are absent.  
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Co-expression of PrPΔ141-231 does not rescue the ΔCD phenotype 
 
The double positive offspring resulting from the breeding of tg155 with two PrPΔCD 
expressing transgenic lines (tg1046 and tg1050) did not differ in terms of phenotype and 
survival from the single positive offspring carrying the PrPΔCD allele only. Given the high 
toxicity of PrPΔCD in tg1050 and the supraphysiological levels of PrPC required to rescue the 
phenotype, the results of the tg155xtg1050 crossing are not surprising. In the case of the 
lower expresser line tg1046, the expression level of PrPΔCD corresponds to that of PrPΔ141−231 
in line tg155, amounting up to about 10% of PrPC expression in the CNS of a wild-type 
mouse (Baumann, Tolnay et al. 2007). This low expression level of PrPΔCD is sufficient to 
induce a strong phenotype, resulting in the death of transgenic mice at 25 days of age, 
indicating that PrPΔCD may have a high affinity for the putative prion protein receptor PrPR.  
One allele of Prnp is required to rescue the phenotype induced by PrPΔCD, which represents 
5 times more protein than PrPΔ141−231. Moreover, because PrPΔ141−231 lacks the globular domain 
of PrPC, its interaction with PrPR might be weaker and require increased levels of PrPΔ141−231. 
Therefore, we cannot conclude that the amino-terminus of PrPC does not convey the 
function of the full-length protein in the absence of a globular carboxy-terminal domain. 
Indeed, while a low amount of a toxic mutant (PrPΔCD) with a potentially high affinity for PrPR 
induces a phenotype, the co-expression of an equimolar amount of a protein devoid of the 
globular domain might not suffice to compete for interaction with PrPR. The absence of 
rescue may thus rather be due to the reduced affinity of PrPΔ141-231 for PrPR and an 
increased molar ratio of PrPΔ141-231 to PrPΔCD may be required to compete for interaction with 
PrPR. 
 
 
 
 
 
 71 
4. Outlook 
 
PrPSc treatment with PK removes the octarepeat region without abrogating infectivity 
(Neary, Caughey et al. 1991). Transgenic mice expressing PrPC deletion mutants 
lacking the octarepeat region are susceptible to prions (Fischer, Rulicke et al. 1996) 
(Shmerling, Hegyi et al. 1998). Together, these findings indicate that the octarepeat 
region of PrP is neither required for infectivity nor for prion propagation. However, PrPC 
variants with truncations extending further than the octarepeat region, disrupting the 
charged cluster 2 alone or in conjunction with the hydrophobic core (figure 9), are not 
convertible into PrPSc, suggesting that the central domain of PrPC is involved in prion 
replication (Shmerling, Hegyi et al. 1998). The hydrophobic core is thus a double-edged 
sword, required both for the physiological function of PrPC and for prion susceptibility. 
The role of the carboxy-terminus of PrPC in prion propagation is less clear. A patient 
heterozygous for a Prnp mutation consisting of an amber mutation at codon 145 was 
reported with a GSS syndrome and PrP amyloid plaques, indicating that a PrPC variant 
lacking the carboxy-domain may be disease-associated (Kitamoto, Iizuka et al. 1993). 
Transgenic mice expressing PrP mutants lacking helix 2 or helix 3 were shown to be 
resistant to prion inoculation (Muramoto, DeArmond et al. 1997). However, such 
mutations led to ER retention of PrP, and the resistance to prions could thus rather be 
due to the mislocalization of the protein than its inability to convert into a PrPSc isoform. 
We plan to inoculate intracerebrally Prnp+/+ and Prnp+/- tg155 mice in order to assess 
the impact of PrPΔ141-231 on prion replication. PrPΔ141-231 may be a template for PrPSc, 
accelerating the course of the disease, or alternatively act as a dominant negative 
mutant, binding and sequestrating PrPSc without converting into a disease associated 
isoform.  
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III. The nasal cavity as an entry site for prions 
 
 
1. Summary and outline of the study 
 
 
Most cases of naturally occurring animal prion diseases have an infectious aetiology 
(Sigurdson and Miller 2003). While the epidemic spread of BSE among cattle in the UK 
during the late 1980’s to mid 1990’s is attributed to transmission through contaminated 
feed (Collee and Bradley 1997), the mechanisms of transmission of other prion 
diseases such as CWD and scrapie remain unknown. Healthy sheep were reported to 
become infected with prions after gazing in a pasture where scrapie infected sheep had 
been kept (Poser 2002), and soil has been shown to bind prions and maintain infectivity 
(Johnson, Phillips et al. 2006), indicating that the environment can be a reservoir for 
prions.  
Many vectors for prion spread have been proposed and experimentally investigated, 
such as saliva, urine and faeces. CWD was experimentally transmitted to healthy 
cervids upon oral inoculation with saliva derived from affected animals (Mathiason, 
Powers et al. 2006); infectivity was detected in the urine of mice inoculated with prions 
and concomitantly suffering from nephritis (Seeger, Heikenwalder et al. 2005); and 
faeces of orally inoculated hamsters were shown to be infectious (Safar, Lessard et al. 
2008). These experiments indicate that natural secretions/excretions from infected 
animals are plausible sources of prion contamination of the environment. 
The routes of entry of prions into the host remain unclear. Oral, cutaneous (scarified 
skin)  and conjunctival portals of entry have been suggested and proven experimentally 
(Andreoletti, Berthon et al. 2000)  (Sigurdson, Spraker et al. 2001)  (Taylor, McConnell 
et al. 1996)  (Scott, Foster et al. 1993). 
We hypothesized that the olfactory system, extensively used for various purposes by 
ruminants, is a site of entry for prions. To model a situation that may occur naturally in 
animals gazing in an environment contaminated with prions, we inoculated mice by 
placing mouse-adapted scrapie prions (Rocky Mountain Laboratory (RML) strain) 
inferior to the nostrils, letting them breathe in the infectivity.  
In a first set of experiments, we inoculated transgenic mice overexpressing PrPC (tga20 
mice) (Fischer, Rulicke et al. 1996) to assess a potential prion transmission through this 
new inoculation route. We show that five out of five mice nasally inoculated with 10-2 
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RML develop terminal scrapie disease signs 141+/-22 days after inoculation, 
establishing nasal prion inoculation as a possible route for prion infection. 
Upon peripheral prion infection, a replication phase in the lympho-reticular system 
(LRS) precedes neuroinvasion (Aguzzi and Heikenwalder 2005). Within the lymphoid 
tissue, follicular dendritic cells (FDCs) were identified as the main prion replication 
compartment (Weissmann, Raeber et al. 2001). FDCs are radioresistant cells of stromal 
origin, located in the germinal centres of lymphoid organs. They have a dual function in 
supporting the formation and maintenance of the lymphoid microarchitecture, and 
assisting affinity maturation of B lymphocytes by trapping unprocessed antigens. Gene 
deletion experiments in mice have shown that signalling by both tumor necrosis factor 
(TNF) and lymphotoxins (LT) is essential for FDC development (Fu, Molina et al. 1997) 
(Koni, Sacca et al. 1997) (Endres, Alimzhanov et al. 1999). Maintenance of pre-existing 
FDCs in a differentiated state requires continuous interaction with B cells expressing 
membrane-bound lymphotoxin-alpha/beta heterotrimers (LT-α/β)) (Gonzalez, Mackay et 
al. 1998), which signal via the LT-β receptor (LTβR) present on FDCs (Ware, 
VanArsdale et al. 1995). Mice lacking either B cells (such as in µMT mice, (Kitamura, 
Roes et al. 1991)) or LTα, LTβ  or LTβR, lack mature FDCs and fail to replicate prions in 
the LRS, preventing the development of cerebral disease (Prinz, Montrasio et al. 2002) 
(Klein, Frigg et al. 1997). Inhibition of the LTβR pathway in mice by treatment with 
LTβR−immunoglobulin fusion protein (LTβR-Ig) leads to the dedifferentiation of mature, 
functional FDCs in spleen and lymph nodes (Gommerman and Browning 2003), 
significantly impairing peripheral prion pathogenesis and delaying the onset of cerebral 
disease (Mabbott, Mackay et al. 2000) (Montrasio, Frigg et al. 2000). The chemokine 
receptor CXCR5 directs lymphocytes towards specific microcompartments (Forster, 
Mattis et al. 1996). In the absence of CXCR5, the distance between germinal centre-
associated FDCs and splenic nerve endings is reduced and prion pathogenesis upon i.p. 
prion challenge is accelerated (Prinz, Heikenwalder et al. 2003), indicating that the 
distance between FDCs and nerve endings is critical for neuroinvasion. 
FDCs trap antigens either as immune complexes via Fcγ receptors or as C3d/C4b-
opsonized antigens through CD21/CD35 receptors. While absence of FcγR has no 
impact on peripheral prion pathogenesis (Klein, Kaeser et al. 2001) , ablation of 
CD21/CD35 in the stromal compartment of the LRS reduces susceptibility to peripheral 
prion inoculation (Zabel, Heikenwalder et al. 2007). Deletion of C3, whose breakdown 
products bind to CD21/CD35 complement receptors, significantly delays neuroinvasion 
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upon i.p. inoculation (Klein, Kaeser et al. 2001) (Mabbott, Bruce et al. 2001). C1q is the 
first component of the classical pathway of the complement system. It can be directly 
activated by binding to pathogens (Ebenbichler, Thielens et al. 1991), leading to 
activation of C4, which in turn binds CD21/CD35. Deletion of C1q has a drastic effect on 
peripheral prion pathogenesis, leading to resistance to low dose peripheral prion 
inoculation (Klein, Kaeser et al. 2001). Taken together, these data suggest that direct 
opsonisation of prions may facilitate peripheral prion pathogenesis by enhancing 
docking to FDCs. 
Although FDCs are critical for LRS prion replication, most efficient peripheral prion 
replication requires both the stromal and haematopoietic compartments of the LRS 
(Kaeser, Klein et al. 2001). TNFR1-/- are fully susceptible to peripheral administration of 
prions and infectivity is detected in lymph nodes despite the absence of mature FDCs 
(Prinz, Montrasio et al. 2002), indicating that other cells than FDCs, probably of 
haematopoietic origin, can maintain replication of prions to titres that are similar to those 
of wild-type mice (Prinz, Montrasio et al. 2002). In addition, cells of haematopoietic 
origin may play an important role in the transport of prions from peripheral entry sites to 
the lymphoid replicative compartment. For example, upon oral challenge with prions, 
dendritic cells (DC) can take up prions and act as a cellular bridge between the gut 
lumen and the LRS (Huang, Farquhar et al. 2002).  DC have also been implicated in 
transport of prions from a cutaneous portal of entry to the draining lymph node (Mohan, 
Hopkins et al. 2005). 
In a second set of experiments that are currently ongoing, we investigate the 
involvement of the LRS in prion pathogenesis upon nasal inoculation. Owing to the 
proximity of the nasal mucosa with the central nervous system (Figure 27), we 
speculate that neuroinvasion occurs directly, without involvement of a replicative step in 
the LRS. To test this hypothesis, we nasally inoculated different mouse models lacking 
components known to be crucial for LRS prion replication. The inoculated mice include 
1) Mice constitutively lacking mature FDCs: JH-/- (lack of the JH gene for antibody heavy 
chain production, leading to the absence of mature B cells); LT-α-/-; LT-β-/-;  LTβR-/- and 
TNFR1-/- mice; 2) Mice lacking mature FDCs following treatment with LTβR-Ig; 3) CR2-/- 
and C1q-/- mice lacking CD21/CD35 or C1q respectively; 4) Mice expressing PrPC on 
neurons only (NSE-PrP); 5) CXCR5-/- mice with FDCs in close vicinity to splenic nerve 
endings; 6) CCR7-/- mice lacking secondary lymphoid-tissue chemokine (SLC) receptor, 
important for the homing of DC to lymph nodes; 7) Appropriate wild-type controls.  
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If prion transmission upon nasal inoculation were to occur independently of a LRS 
replication phase, the incubation time in all groups should not differ from that of the 
appropriate wild-type controls, since none of these mouse models have impaired central 
prion pathogenesis. If the LRS were to be required for efficient nasal transmission of 
prions, the panel of transgenic and knock-out mice inoculated here should allow locating 
the determinant steps of peripheral prion pathogenesis upon nasal inoculation.  
 
 
 
 
 
 
 
 
 
Figure 27 
Schematic drawing of the mammalian olfactory system In mammals, the olfactory epithelium lies at 
the roof of the nasal cavity and contains olfactory sensory neurons whose axons form the olfactory nerve, 
which belongs to the peripheral nervous system. This nerve crosses the cribriform bone and forms 
glomeruli within the olfactory bulb. Inside the glomeruli, the axons contact the dendrites of mitral cells. 
Mitral cells project their axons to brain areas including the piriform cortex, the medial amygdale and the 
entorhinal cortex. 
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Figure 28 
Tumor necrosis factor (TNF), lymphotoxin (LT) and LIGHT ligands, and their receptors. Cell bound 
and soluble TNF and soluble LT homotrimers bind both TNFRp55 (TNFR1) and TNFRp75 (TNFR2). 
Soluble LT 3 also binds to herpes virus entry mediator (HVEM). Membrane-bound LT 1 2 is only 
known to bind LT R, but not the TNFRp55, TNFRp75 or HVEM molecules. LIGHT has been shown to 
bind to three receptors, HVEM, LT R and DcR3. LIGHT (TNFSF14), tumor necrosis factor ligand 
superfamily, member 14; DcR3, decoy receptor 3. From Curr Opin Allergy Clin Immunol 2002 
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      2. Results 
 
 
2.1 Expression of PrPC in the respiratory tract and olfactory bulb of wild-
type, tga20 and NSE-PrP mice 
 
 
PrPC is an absolute prerequisite for prion replication competence, and PrPC expressing 
tissue is required for prion spread from peripheral sites to the CNS (Blattler, Brandner et 
al. 1997) and within the CNS (Brandner, Raeber et al. 1996). While PrPC expression in 
the nervous and lymphoid tissue is well characterized, less is known about its 
expression pattern in the respiratory tract.   
We screened PrPC expression in the respiratory tract and olfactory bulb of transgenic 
mice overexpressing PrPC (tga20) or expressing PrPC exclusively on neurons (NSE-
PrP) and wild-type mice. We show that PrPC is expressed all along the respiratory tract, 
from the olfactory epithelium to the lungs, as well as in the olfactory bulb (Figure 29). 
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Figure 29 
PrPC expression in the respiratory tract of wild-type, NSE-PrP, and tga20 mice. A Trachea. Lane 1 
to 3: wild-type mouse; 10ug, 5ug and 2.5ug total protein respectively. Lane 4: Prnp0/0 mouse. Lane 5 to 7: 
NSE-PrP mouse; 10ug, 5ug and 2.5ug total protein respectively. Lane 8 to 10: tga20 mouse; 10ug, 5ug 
and 2.5ug total protein respectively. B Lung. Lane 1 to 3: wild-type mouse; 25ug, 12.5ug and 6.25ug total 
protein respectively. Lane 4: Prnp0/0 mouse. Lane 5 to 7: NSE-PrP mouse; 25ug, 12.5ug and 6.25ug total 
protein respectively. Lane 8 to 10: tga20 mouse; 25ug, 12.5ug and 6.25ug total protein respectively. C 
Olfactory bulb. Lane 1 to 3: wild-type mouse; 7.5ug, 3.75ug and 1.9ug total protein respectively. Lane 4: 
Prnp0/0 mouse. Lane 5 to 7: NSE-PrP mouse; 7.5ug, 3.75ug and 1.9ug total protein respectively. Lane 8 to 
10: tga20 mouse; 7.5ug, 3.75ug and 1.9ug total protein respectively. D Respiratory and olfactory 
epithelium. Lane 1 to 3: wild-type mouse; 10ug, 5ug and 2.5ug total protein respectively. Lane 4: Prnp0/0 
mouse. Lane 5 to 7: NSE-PrP mouse; 10ug, 5ug and 2.5ug total protein respectively. Lane 8 to 10: tga20 
mouse; 10ug, 5ug and 2.5ug total protein respectively. PrPC expression gives rise to 3 bands between 37 
and 25 kD, corresponding to di-, mono- and unglycosylated species. Upper blot probed with POM1 and 
lower blot with anti-β actin. 
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2.2 Nasal inoculation with RML leads to terminal scrapie disease in tga20 
mice 
 
To test whether the nasal cavity may be an entry site for prions, we intranasally 
inoculated nine tga20 mice which overexpress PrPC under the control of the 
endogenous PrPC promoter (Fischer, Rulicke et al. 1996), and four Prnp0/0 mice. The 
inoculation technique is described in the materials and methods section. Briefly, a total 
of 40ul 10-2 mouse adapted sheep prions (RML 5, fifth passage of the RML strain in 
CD1 mice) were placed under the nostrils of the mice, which breathed it in.  
Of the nine tga20 mice, four mice were sacrificed sixty days post-inoculation (dpi) and 
the remaining five mice were euthanized at end-stage scrapie disease (clinical 
assessment).  
Sixty days post-inoculation, all mice were asymptomatic, and no PK resistant material 
was detected by conventional western blotting in the respiratory tract, LRS and CNS of 
the tga20 mice (Figure 30). Approximately eighty days later, the remaining five mice 
developed end stage scrapie disease. Western blot and histoblot analysis of the LRS 
and the CNS revealed the presence of PK resistant material in both compartments. The 
mean survival time was 141 dpi +/- 22. The relatively high standard deviation is most 
probably attributable to the inoculation route. Indeed, while the same amount of 
inoculum was given to all mice, the amount that was effectively breathed in by each 
mouse may vary. 
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Figure 30 
Intranasally inoculated tga20 mouse, 60 days post inoculation. A Western blot of spleen, mesenteric 
lymph nodes (mln) and bronchal lymph nodes (bln) of a tga20 mouse. 60 days post inoulation, with (PK+) or 
without (PK-) proteinase K digestion. No PK resistant material is detectable. Positive control: CNS of a 
terminally sick wild-type mouse. B Western blot of the hemispheres, cerebellum and olfactory bulbs of a 
tga20 mouse 60 days post inoculation, with (PK+) or without (PK-) proteinase K digestion. No PK resistant 
material is detectable. Positive control: CNS of a terminally sick wild-type mouse. C Western blot of trachea, 
lung, and olfactory epithelium (olf. epith.) of a tga20 mouse, 60 days post inoculation, with (PK+) or without 
(PK-) proteinase K digestion. No PK resistant material is detectable. Positive control: CNS of a terminally 
sick wild-type mouse. 
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Figure 31 
Survival plot of tga20 and Prnp0/0 mice intranasally inoculated with 10-2 RML5. Five tga20 mice and 
four Prnp0/0 mice were intranasally inoculated with 10-2 RML5. All tga20 mice developed terminal scrapie 
signs and were euthanized. The mean incubation time was 141 dpi +/- 22 days. Red cicles, tga20 mice. 
Green circles Prnp0/0 mice. 
 
 
Figure 32 
Histoblots of spleen and cerebellum of terminally sick tga20. A Spleen of a terminally sick tga20 
mouse inoculated intranasally showing accumulation of PrPSc. Left panel: no proteinase K (PK) treatment. 
Right panel:  treatment with 100 ug/mL PK. Detection with POM1. B Cerebellum of a terminally sick tga20 
mouse inoculated intranasally showing accumulation of PrPSc. Left panel: no proteinase K (PK) treatment. 
Right panel:  treatment with 100 ug/mL PK. Detection with POM1. 
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Figure 33 
Terminally sick intranasally inoculated tga20 mouse. A Western blot of spinal cord and cerebellum of a 
terminally sick tga20 mouse with (PK+) or without (PK-) proteinase K digestion. PK resistant material is 
detectable in both compartments of the CNS. Positive control: CNS of a terminally sick wild-type mouse. B 
Western blot of lung, trachea and bronchial lymph node (bln) of a terminally sick tga20 mouse with (PK+) or 
without (PK-) proteinase K digestion. PK resistant material is detectable in none of these organs. Positive 
control: CNS of a terminally sick wild-type mouse. C Western blot of the olfactory epithelium and the brain 
hemispheres of a terminally sick tga20 mouse with (PK+) or without (PK-) proteinase K digestion. PK 
resistant material is detectable in the hemispheres but not in the olfactory epithelium. Positive control: CNS 
of a terminally sick wild-type mouse. D Western blot of the nasal associated lymphoid tissue (NALT) and the 
spleen of a terminally sick tga20 mouse with (PK+) or without (PK-) proteinase K digestion. PK resistant 
material is detectable in the spleen but not in the NALT. Positive control: CNS of a terminally sick wild-type 
mouse. 
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2. Discussion and outlook 
 
 
The natural routes of prion spread among flocks of animals are unknown. The oral 
portal of entry has been extensively studied, and while this route of transmission is 
possible, its efficiency is low (Prinz, Huber et al. 2003). At the time we started this study, 
nothing was known about a potential transmission through the respiratory tract. We 
hypothesized that the nasal cavity may be an entry site for prions, and assessed this 
possibility by intranasally inoculating transgenic mice overexpressing PrPC (tga20). We 
show that five out of five tga20 mice intranasally inoculated with RML develop terminal 
scrapie disease, identifying the nasal cavity as a possible entry site for prions. 
The determination of the efficiency of intranasal prion infection requires endpoint 
titration of RML and determination of the LD50 (lethal dose for 50% of inoculated mice) 
(Prusiner, Cochran et al. 1982), followed by comparison of the infectivity titres upon 
intranasal inoculation with those of established infection routes such as oral, 
intraperitoneal (i.p.) and intracerebral (i.c.) routes. Although these titration experiments 
have not been done yet, the nasal route of infection appears to be more efficient than 
the oral route. Indeed, the same inoculum administrated orally fails to elicit disease in 
tga20 mice, while inducing 100% lethality upon intranasal inoculation (results 
communicated by Mathias Heikenwälder).  
Given the anatomical proximity of the respiratory and digestive tracts, it is technically 
difficult to exclude that part of the intranasal inoculum is not swallowed by the mouse. 
However, because efficient prion transmission through the oral route requires higher 
doses than the one used in this study, we can argue that the respiratory tract 
participates to a great extent in the transmission of prions upon intranasal inoculation. 
At sixty days post inoculation, PrPSc was neither detected in the LRS nor in the CNS of 
intranasally inoculated tga20. This stands in contrast with what is known for other 
peripheral routes of inoculation (oral and i.p.), where PrPSc levels rise rapidly in the LRS 
of both wild-type and tga20 mice, maintaining a plateau level throughout the course of 
the disease. Recently, a publication reported the high efficiency of prion transmission 
through the nasal cavity in hamsters using an inoculation protocol similar to ours 
(Kincaid and Bartz 2007). They further report the presence of PrPSc in the LRS four 
weeks after nasal inoculation. Our preliminary results may indicate that, similarly to what 
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is observed in tga20 mice inoculated in the sciatic nerve or in the footpad (Glatzel and 
Aguzzi 2000), PrPC overexpression bypasses the need for a replication phase in LRS 
upon nasal route in tga20 mice. The study of prion transmission upon nasal inoculation 
in wild-type mice (ongoing) will allow us to address this question and compare our 
results with those reported for hamsters.  
At end-stage disease, PrPSc was present in both the LRS and the CNS. These findings 
do not allow conclusions on the requirement the LRS for a replication step before 
neuroinvasion. Indeed, upon i.c. prion inoculation of wild-type and tga20 mice, PrPSc is 
detectable in the LRS at end stage disease, although a replication step in the LRS is not 
required for CNS disease. The requirement of the LRS for prion pathogenesis upon 
nasal inoculation will be best addressed in the second and ongoing part of this project. 
The identification of novel pathways of prion transmission may lead to the reevaluation 
of tissues and organs that were previously assumed to be prion free. It may also lead to 
the identification of situations of potential iatrogenic transmission of prion diseases. 
PrPSc has been detected upon autopsy in the olfactory epithelium of patients suffering 
from sCJD (Zanusso, Ferrari et al. 2003). While there is no epidemiological evidence for 
direct transmission of prions from individual to individual (Linsell, Cousens et al. 2004), 
the nasal cavity may be a route of indirect prion transmission through contaminated 
respiratory devices. However, it remains to be determined whether sCJD patients carry 
PrPSc in their olfactory mucosa at earlier time-points of the disease, when medical 
procedures may be done in the absence of the diagnosis of sCJD. 
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  V. Material and methods 
 
 
1. RNA extraction and cDNA synthesis 
 
Total RNA from 8 weeks old mouse brains was isolated using 1mL Trizol (invitrogen) 
per 50mg of tissue. 1ug RNA was used for cDNA synthesis. Prior to cDNA synthesis, 
contaminating genomic DNA was removed. cDNA synthesis was done with QuantiTect 
Reverse transcription Kit (Qiagen) according to the manufacturer’s instructions.  
 
2. Construction of the PrPΔ141-231 transgene 
 
Total mouse brain cDNA was amplified using the primer set SY6 and SY7 which 
introduce  BamHI and SalI cloning sites at the 3’ and 5’ ends of the ORF of PrPC . 
PrPC was cloned into the cloning vector pBSK (pBSK-PrP). This plasmid served as a 
template for the following cloning steps. 
An XbaI cloning site was introduced by PCR in the PrP ORF just before the GPI signal 
sequence (amino acid 231). The primer sets used were SY6/SY6a and SY7a/SY7.  
An amino-terminal insert was amplified from pBSK-PrP using the primer set SY6/SY8 
which introduces BamHI and XbaI cloning sites before the start codon and after amino 
acid 140, respectively.  
pBSK-PrP and the amino-terminal insert were digested with BamHI and XbaI, and the 
open vector and the insert were ligated, to generate a construct consisting of the first 
140 amino acids of PrPC directly linked to the GPI signal (PrPΔ141-231). 
The transgene was then transferred to the expression vector pBMN, by digestion with 
BamHI and SalI followed by ligation.  
Primers: 
SY6 (forward): 5’-CGCGGATCCAATTTAGGAGAGCCAAGCAGA-3’ 
SY6a (reverse): 5’-CGCTCTAGAACGTCGCCCGTCGTAATAGGC-3’ 
SY7a (forward): 5’-CGCTCTAGAGACGGGAGAAGATCCAGCAGC-3’ 
SY7 (reverse): 5’-ACGCGTCGACCACGAGAATGCGAAGGAACA-3’ 
SY8 (reverse): 5’-ACGCTCTAGACCAGTCGTTGCCAAAATG-3’ 
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3. Transduction of cells 
 
Retroviral particles were generated with the Phoenix Retrovirus Expression System 
(Orbigen), following the manufacturer’s instructions. The adequate cell line (N2a or Hpl) 
was transduced, and cells were harvested and processed for downstream experiments 
(Western blotting or flotation assays).  
 
 
4. Immunoprecipitation and western blotting 
 
Paramagnetic beads (tosylactivated M280 Dynabeads, Dynal) were conjugated with 
POM12 or mouse IgG1 isotype control antibody according to the manufacturer’s manual 
(3 ug antibody per 107 beads). Protein concentrations of 10 % brain homogenates 
prepared in RIPA buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 0.1% SDS, 1% NP-40) 
were determined by BCA (bicinchoninic acid) Protein Assays (Pierce), according to the 
manufacturer’s instructions. The homogenates were incubated with the beads, washed 
and resuspended in RIPA containing loading buffer (NUPAGE LDS Sample Buffer, 
Invitrogen). And subjected to Western blotting. Blots were blocked with 5% Topblock 
(Sigma) and incubated with the appropriate POM antibody (1:10’000, Polymenidou et al 
2005) in 1% Topbloc. For detection, rabbit anti-mouse IgG1-HRP (Zymed, 1:10’000) 
was used . After adding substrate (SuperSignal West Dura, Pierce), blots were analyzed 
with a FUJI LAS 3000 imaging system. 
 
 
 
5. Flotation assays 
 
Flotation of detergent insoluble complexes was performed as described (Naslavsky et 
al., 1997). Briefly, brain homogenates were extracted for 2 h on ice in cold lysis buffer 
(150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1% Triton X-100); total protein: 
1mg in 1 mL. Extracts were mixed with two volumes (2 ml) of 60% Optiprep (Nycomed) 
to reach a final concentration of 40%. All lysates were loaded at the bottom of Beckman 
ultracentrifuge tubes. A 5–30% Optiprep® step gradient in TNE (150 mM NaCl, 25 mM 
Tris–HCl, pH 7.5, 5 mM EDTA) was then overlaid onto the lysate (8.4 ml of 30% 
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Optiprep® and 3.6 ml of 5% Optiprep®). Tubes were centrifuged for 24 h at 4°C in a 
TLS55 Beckman rotor at 100 000 g. Fractions (1 ml) were collected from the top of the 
tube and processed for immunoblotting. 
 
 
6. Quantitative Real Time PCR (qPCR) analysis and primers 
 
Quantitative real-time PCR was performed using SYBR Green Master Mix (Qiagen) on a 
7900HT Fast Real-Time PCR System (Applied Biosystems) using default cycling 
conditions. Expression levels were normalized using Gapdh. The Prnp primers were 
design to amplify the amino-terminal domain of PrPC only, so that the amplification 
product of Prnp and the PrPΔ141-231 transgene would be the same. 
Primers: 
Gapdh forward primer: 5’-CCACCCCAGCAAGGAGACT-3’ 
Gapdh reverse primer: 5’-GAAATTGTGAGGGAGATGCT-3’ 
Prnp forward primer: 5’-ATGGCGAACCTTGGCTAC-3’ 
Prnp reverse primer: 5’-AAAATGGATCATGGGCCTG-3’ 
 
 
7. Generation of the transgenic mouse 
 
The phg plasmid containing the PrPΔ141-231 ORF was propagated in Escherichia coli XL1 
blue, the minigene was excised  with  NotI and SalI (see figure 16 B), processed as 
described (Fischer et al, 1996), and injected into fertilized Prnp+/+ oocytes (B6D2F1/Crl) 
by standard procedures (Rulicke, 2004). The transgene positive founders were then 
crossed with Prnp0/0 ZHI mice in order to obtain transgene positive mice on a Prnp0/0 
background. Transgenes were identified by PCR using the exon 2 forward primer pE2 
and the non-coding region at 3’ of exon 3 reverse primer 3’NC . The fragment size of the 
transgene was 647bp. In order to outbreed the Prnp+ allele, PCR analysis was carried 
out using primers P10 (forward primer, Prnp exon 3), 3'NC (reverse primer), and P3 
(reverse primer, neoR gene); P10 and 3'NC gave a 542 bp signal for the Prnp+ allele 
and P3 and 3'NC gave a 362 bp product for the Prnp0 allele. In the PCR, the transgene 
was also detected as a 269 bp product. 
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Primers: 
pE2: 5’-CAA CCG AGC TGA AGC ATT CTG CCT-3’ 
3’NC: 5'-CCC TCC CCC AGC CTA GAC CAC GA-3’ 
P10: 5'-GTA CCC ATA ATC AGT GGA ACA AGC CCA GC-3’ 
P3: 5'-ATT CGC AGC GCA TCG CCT TCT ATC GCC-3’ 
 
 
8. Southern blot analysis 
 
Mouse tail biopsies were digested in lysis buffer (10mM Tris-HCl pH 8, 5mM EDTA pH 8, 
1% SDS, 300 mM NaAC pH 7.6 and 100 µg/ml Proteinase K) overnight at 55°C under 
constant agitation. Purified genomic DNA (50 µg) was digested overnight (EcoRI, 100 
U) and separated on 0.7% agarose gels. Completeness of the restriction digest and 
DNA separation was checked by ethidium bromide staining. Genomic DNA was 
transferred by overnight blotting in 20xSSC (3M NaCl, 0.3M Na3Citrate, pH 7.4) onto a 
positively charged biodyne B membrane . The blot was marked, washed for 5 min in 2 × 
SSC, UV-crosslinked and prehybridized according to Church and Gilbert (1984). After 
hybridization (overnight at 65°C) with a radioactively labeled probe (PrPΔ14-231 ORF), the 
blot was washed and membranes were subjected to autoradiography using a 
PhosphoImager (Molecular Dynamics). Images were scanned and signals were 
quantified with Aida 2.41 imaging software. For probe labelling, template DNA (PrPΔ14-231 
ORF, 50 ng) was diluted in sterile water and random primers (nonamers or hexamers) 
were added (Prime-IT® II; Random Primer labelling kit cat# 300385; Stratagene). After 
gentle mixing, incubation was performed at 95°C for 5 min. Brief centrifugation was 
followed by 3 min incubation on ice. This was followed by addition of 5 × primer buffer 
(−dCTP), radioactively labeled [α−32]P-dCTP (corresponding to 25 µCi; Amersham 
Biosciences), and Klenow 5 U/µl (Prime-IT® II; Random Primer labelling kit cat# 
300385). For primer elongation, the probe was incubated at 37°C for 75 min. For 
purification, the QIAquick PCR purification kit was used according to the manufacturer's 
manual (Quiagen). 
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9. Pulse-chase experiment 
Cerebellar slice cultures were prepared as described (Falsig and Aguzzi 2008). Four 
inserts containing eight cerebellar slices were prepared using tg155 mice and one insert  
was prepared using Prnp0/0 mice as control for the specificity of the immunoprecipitation. 
The slices were kept in culture for four weeks prior to the pulse-chase experiment. The 
inserts containing the slices  were washed twice with phosphate-buffered saline (PBS) 
and starved for 1 hour in RPMI medium without methionine/cysteine containing 1% 
foetal calf serum. Labeling was carried out by adding 400 µCi/ml [35S]Met/Cys to the 
medium for 30 minutes. After incubation, the slices were washed twice in cold PBS and 
harvested with RIPA buffer (pulse slices) (50 mM Tris-HCl pH8, 150 mM NaCl, 0.1% 
SDS, 1% NP-40) or incubated at 37 °C for 15 minutes, 30 minutes, 60 minutes and 120 
minutes in complete culture medium (chase slices). After appropriate chase times, the 
slices were washed with PBS and lysed with cold RIPA   buffer and kept on ice for 30 
minutes. Cell debris were removed by centrifugation for 10 minutes at 18,000 × g. The 
supernatents were immunoprecipitated using POM12 coupled Dynabeads as described 
in section 4. The material released from the beads by boiling was loaded on two SDS-
PAGE. One gel was blotted on a nitrocellulose membrane and the membrane probed 
with POM11. The second gel was desiccated and  subjected to autoradiography. The 
signals were quantified by sing a PhosphoImager (Molecular Dynamics).  
 
10. Morphological analysis 
 
Brains were removed and fixed in 4% formaldehyde in PBS, pH 7.5, paraffin embedded, 
and cut into 2–4 µm sections. Sections were stained with hematoxylin and eosin (H&E) 
and GFAP (glial fibrillary acidic protein; activated astrocytes).  
 
 
11. Prion inoculation of mice 
 
Mice were inoculated with a 1% homogenate of heat- and sarcosyl-treated brain 
prepared from mice infected with the Rocky Mountain Laboratory (RML) scrapie strain, 
5th passage in CD1 mice (RML5). Mice were anaesthetized with Xylazin/Ketamin and 
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held horizontally during the entire intranasal inoculation procedure. Ten µl were 
deposited under each nostrils, and the mouse was allowed to breath in the inoculum. A 
pause of 10 minutes was made before the procedure was repeated once, in order to 
inoculate a total of forty ul. Mice were monitored every third day, and scrapie was 
diagnosed according to standard clinical signs. 
 
 
 
12. Western blot of infected mice 
Homogenates (10%, w/v) of the appropriate tissues  were prepared as described 
(Bueler, Aguzzi et al. 1993) and, where indicated, digested with 20 µg/ml proteinase K 
for 30 min at 37 °C. The samples were then electrophoresed through 12%–SDS 
polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were 
probed with POM1 (1:10’000, Polymenidou et al 2005) in 1% Topbloc to mouse PrPC, 
and with anti-β-actin to mouse β-actin. The blots were developed by enhanced 
chemiluminescence (Amersham).  
 
13.  Histoblot 
 
The histoblot technique was performed according to protocols of Taraboulos et al. 
(Taraboulos, Jendroska et al. 1992).  Frozen sections of 8 µm thickness were mounted 
on uncoated glass slides and immediately pressed on a nitrocellulose membrane wetted 
in lysis buffer. Membranes were air-dried for at least 24 h. For detection, they were 
rehydrated in TBST, and limited proteolysis was performed using PK concentrations of 
50 and 100 µg/ml at 37 °C for 4 h. Blots were then denatured in 3 M guanidinium 
thiocyanate for 10 min and blocked for 1 h in 5% non-fat milk serum. Incubation with 
primary antibody POM1 was carried out at a dilution of 1:2000 in 1% non-fat milk serum 
at room temperature for 1 h. Detection was accomplished with an alkaline phosphatase-
conjugated goat anti-mouse antibody at a concentration of 1:2000. Visualization was 
achieved with nitro blue tetrazolium and bromo-chloro-indolyl phosphate according to 
the protocols of the supplier. 
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